

PERFORMANCE. PROVEN EFFECTIVENESS WITHIN A WIDE SAFETY MARGIN.



Month after month. Year after year. The evidence continues to accumulate.

While Roche Laboratories already knows more about the performance of Librium than anyone else, we keep on learning more every day.

For example, the highly favorable benefits-to-risk ratio of Librium is a well-documented matter of record.

It's a record which shows that Librium is seldom associated with serious side effects. That Librium rarely interferes

with mental acuity. That most common side effects are dose-related and therefore—to a large extent—avoidable.

As with all CNS-acting drugs, however, patients should be cautioned against hazardous activities requiring complete mental alertness and against combined effects with alcohol.

Proven performance within a wide safety margin. Basically, that's what Librium is all about:

LIBRIUM® chlor diazepam HCl/Roche THE ANXIETY-SPECIFIC

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of anxiety and tension occurring alone or accompanying various disease states.

Contraindications: Patients with known hypersensitivity to the drug.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards. **Precautions:** In the elderly and debilitated, and in chil-

dren over six, limit to smallest effective dosage (initially 10 mg or less per day) to preclude ataxia or oversedation, increasing gradually as needed and tolerated. Not recommended in children under six. Though generally not recommended, if combination therapy with other psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of potentiating drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Paradoxical reactions (e.g., excitement, stimulation and acute rage) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely in patients receiving the drug and oral anticoagulants; causal relationship has not been established clinically.

Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated.

These are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances syncope has been reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extensor muscle symptoms, increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and liver function tests advisable during prolonged therapy.

Supplied: Librium® Capsules containing 5 mg, 10 mg, or 25 mg chlor diazepam HCl. Librium® Tablets containing 5 mg, 10 mg or 25 mg chlor diazepam.

Roche Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Medical Tribune

© 1976, Medical Tribune, Inc.

and Medical News

Vol. 17, No. 25

world news of medicine and its practice—fast, accurate, complete

Wednesday, August 4, 1976

Exclusive Interview:

Dr. Cooper Defends Swine-Type Flu Shots

"We Had No Choice... but to Take the Action We Did," Says HEW Official

Medical Tribune Report

WASHINGTON—In an exclusive interview with rising debate on the crash program to immunize over 200 million Americans against swine-type influenza, Dr. Theodora Cooper, Assistant Secretary for Health, Department of Health, Education and Welfare, stressed that the government's vaccination decision was an essential and responsible one based on fundamental scientific judgments in the absence of hard data.

"We had no choice as public officials but to take the action we did to protect the public health, even though we do

See Editorials on Page 11

we know for sure there will actually be an epidemic of influenza this fall or winter," Dr. Cooper said.

Besides the validity of mounting such a program, areas covered in the interview by Dr. Arthur M. Sackler, International Publisher of Medical Tribune, included: Why the vaccine was not stockpiled and other options studied; why the government does not embark on crash programs for other "epidemic" diseases such as cardiovascular disease, and the differences in handling the vaccine program and

Continued on page 22



DR. COOPER

Dr. Sackler Questions Gov't Procedures:

Text of Interview: Part I

It seems to me that the decision for our national effort to head off a swine flu epidemic is based not on hard data but rather on scientific judgment. Is that true?

You are right as rain about the decisions involved in this program. They are based on medical and scientific judgments. Frequently I am asked if the swine flu program sets a precedent for similar actions against other influenza viruses or other diseases in the future. I reply that these will have to be judged on their own merits just as this issue was decided by the best public health and scientific expertise we could bring to bear.

Continued on page 23

Tumor-Specific Antigen Aids Recovery from Lung Cancer

By KRISTIN WHITE
Special Tribune Correspondent

NEW YORK — Mobilizing the immune system to eliminate any lung cancer cells lingering after surgery and adjuvant chemotherapy offers a dramatic therapeutic promise, according to Dr. Thomas H. M. Stewart and Jules E. Harris, of the University of Illinois, and Ariel C. Hollinshead, Ph.D., Pro-

fessor of Medicine at George Washington University Medical Center in Washington, D.C.

Dr. Hollinshead was recently elected Medical Women of the Year "in recognition of her pioneer work in separating tumor-related antigens from the cell surface, and in showing the reactivity of purified antigens for specific types

Continued on page 8

Immunologic Link?

Progesterone Seen Preventing Fetal Rejection

By NATHAN HORWITZ
Medical Tribune Staff

SAN FRANCISCO—Evidence that progesterone may be a vital link to preventing immunologic rejection of the fetus by the mother was reported here by a team at the University of California San Francisco.

Studies showing that the hormone exerts a powerful local immunosuppressive effect within the placenta, thereby protecting the fetus against rejection, were described by Penati K. Sileri, Ph.D., who said the findings could have far-ranging implications in transplantation surgery and in the treatment of spontaneous abortion.

Speaking at the meeting of the Endocrine Society, Dr. Sileri, who is Professor of Obstetrics-Gynecology at UCSF, said the team's animal experiments and in vitro studies of human cell cultures have provided the first evidence for the long-held but never confirmed hypothesis that progesterone may exert the same immunosuppressive in utero effect as that of cortisol or glucocorticoids in transplantation management.

An important observation to emerge from the studies, Dr. Sileri reported, is

Continued on page 6

Healing of Hip Joint May Avoid Surgery in Juvenile Arthritis



10/75
A 12-year-old girl, age 12, with systemic JRA for nine years, shows narrowing of joint spaces and subchondral cysts of acetabulum and femoral heads. After three years, following intensive physical therapy and salicylates, indometh-



acin, and other anti-arthritis drugs, x-ray (right) shows widening of joint spaces and sharp cortical margins of the acetabulum and femoral heads. Before treatment, girl relied on canes to walk; three years later she could ride a bicycle. See page 3.

Purchasing

Purchasing
Manager
Buyer
Manager
Supply Chain Manager

Director

Pharmaceuticals Ltd
Mortlake Road

Placental Progesterone May Protect Fetus From Rejection

Continued from page 1

In control animals, the cotton-wrapped implants were, within one week, surrounded by granulomatous tissue and adhesions which anchored them to the underlying fascia, the investigator reported. "In marked contrast, the progesterone-containing capsule elicited little if any inflammatory response and lay free at the site of implantation." In the animals with the hamster skin implants, at 21 days, "Tissue that was adjacent to progesterone-containing capsules remained in a healthy viable state, whereas the control skin was completely destroyed, as expected," Dr. Siiteri said.

On the basis of the observation that high concentrations of progesterone exert anti-inflammatory and immunosuppressive activity, the team studied the hormone's effect in cultures of human mixed lymphocytes, and found that 1-10 $\mu\text{g}/\text{ml}$ of progesterone exerted "significant suppression" and 20 $\mu\text{g}/\text{ml}$ "virtually complete inhibition" of lymphocyte reactions.

Similar to Glucocorticoids

"The studies thus establish that progesterone, in sufficiently high concentrations, possesses activity similar to that of glucocorticoid hormones which are commonly used to achieve im-

munosuppression in transplant patients," Dr. Siiteri declared, adding: "Other lines of evidence are consistent with the hypothesis that progesterone provides immunosuppression during pregnancy. A fall in progesterone production occurs in many species near the end of normal gestation."

In an interview, he said that the implications of his group's work have aroused interest in two areas of clinical investigation: one is the possibility that progesterone in high concentrations may be employed to exert a local im-



Evidence that progesterone protects fetus against maternal rejection by exerting immunosuppressive effect on placenta may have implications in transplant surgery and treatment of spontaneous abortion. Above, in rats with hamster skin implants, tissue adjacent to progesterone-filled silastic tubes (right) remains viable, with an inflammatory response evident. Empty control tubes (left) become encased in granulomatous tissue; hamster skin below tubes becomes necrotic.

munosuppression in transplant patients," Dr. Siiteri declared, adding: "Other lines of evidence are consistent with the hypothesis that progesterone provides immunosuppression during pregnancy. A fall in progesterone production occurs in many species near the end of normal gestation."

In an interview, he said that the implications of his group's work have aroused interest in two areas of clinical investigation: one is the possibility that progesterone in high concentrations may be employed to exert a local im-

munosuppressive effect in organ transplant without affecting the host's total immune system; the other is the use of progesterone in chronic abortion. Previous attempts to forestall abortion by giving pregnant women progesterone have been unsuccessful, Dr. Siiteri suggested, because systemic administration was employed, thus failing to achieve high local uterine levels. But "new solutions, based on our observations, may help to reduce premature birth, which is a major obstetrical problem," he declared.

major trace elements—but no difference was found in serum samples.

However, calcium and magnesium behave differently in the body. While calcium is found predominantly in blood serum, magnesium stays mainly inside muscle cells, especially in heart muscle where it plays a vital role related to the heart's energy requirements, Dr. Anderson explained.

Autopsy Studies

A further line of attack therefore was comparative and involved autopsy studies done on accident victims and heart attack victims in soft and hard water areas. Comparisons between heart muscle taken from heart attack victims and from the presumably

healthy accident victims in the soft water area showed the difference.

"The comparison confirmed low levels of myocardium magnesium in victims of heart attacks with a mean value of 22% lower than in the corresponding value in accidental deaths," Highly refined North American diets, Dr. Anderson pointed out, may be magnesium deficient.

"It would appear that in Ontario at least, the contribution of water-borne magnesium to total dietary intake may be critical; that some residents of soft-water areas are in a state of subclinical magnesium deficiency. If these individuals suffer a myocardial infarction, they may then be at increased risk of developing a fatal cardiac arrhythmia."

[of the lungs] involves recruitment of nonventilated alveoli or progressive overdistention of these structures."

When more alveoli are brought into action by CNP, arterial oxygen is remarkably improved, as in the two patients, he noted. However, alveolar overdistention could lead to compromised lung compliance and a pulmonary air leak, as in the four who died, Dr. Sanyal cautioned. The possibility of an "optimal pressure" for CNP therapy should be investigated, he said.

While the exact mechanism of action of CNP is not clear, he added, an increase in vascular transmural pressure caused by the continuous negative pressure could increase pulmonary blood flow by decreasing pulmonary vascular resistance and serve to explain the enhanced arterial blood oxygenation.

His coworkers, also at the hospital, included Thomas L. Avery, PhD, and Drs. Mohinder K. Thapar, Walter T. Hughes, and Scott Harris, all in the department of cardiopulmonary services.

O₂ Given to All

"Either pentamidine isethionate or trimethoprim-sulfamethoxazole as well as chlorpheniramine, intravenous fluids, and oxygen were administered to all patients," he added.

As respiratory distress progressed, the patients were placed "in an Emerson tank respirator without bellows, and hooked up to a source of continuous negative pressure," Dr. Sanyal said in an interview. With this pressure constantly applied outwardly, "the response

Cardiac Arrhythmia Deaths Linked to Low Mg Intake

Medical Tribune World Service

MONTREAL—Why do people who live in soft water areas die more often of cardiac arrhythmias than people in hard water areas? Researchers in Ontario are trying to find the answer. A link with water-borne magnesium is suggested.

"As in other parts of the world, death rates from ischemic heart disease in the Province of Ontario show an inverse correlation with the hardness of the local water supply. This relationship has been shown to be due largely to an excess of sudden deaths in the soft water areas—due presumably to an increased tendency to cardiac arrhythmias," Dr. Terence W. Anderson, of the Department of Preventive Medicine and Biostatistics, University of Toronto, told the Second Annual Symposium on Magnesium.

"The evidence in Ontario suggests that a water factor is operative here. The actual number of infarctions is probably not greatly different in the various regions. What is different is a tendency to go into abnormal rhythms and sudden death," he said.

"Magnesium deficiency is known to produce neuromuscular irritability. We have investigated the possibility that residents of soft water areas have less magnesium in the myocardium than residents in hard water areas."

The research described by Dr. Anderson has been going on for several years. Ontario is a province where water varies considerably, from very soft to very hard. Their earlier findings in two cities confirmed that the percentage of sudden deaths following at-

rhythms was higher in soft than in hard water cities, and that held true right across the age range in males and females.

"This was not attributable to it being easier to get to hospital in one city than another. The two cities had similar facilities. In fact, a higher percentage of arrhythmic deaths persisted after the patients were admitted to hospital."

Their study then looked principally at calcium and magnesium serum levels in subjects in the two areas—calcium and magnesium being water's

Negative Chest-Wall Pressure Aids Ca Patients' Pneumonia Survival

By MICHAEL HERRING
Medical Tribune Staff

NEW ORLEANS—Ten out of 14 young, immunosuppressed, cancer patients have survived acute episodes of "diffuse pneumonia" with the help of continuous negative chest-wall pressure (CNP) therapy, a new means of improving arterial oxygenation in hypoxia.

In addition to helping achieve the high survival rates for this formidable complication, "CNP therapy" eliminates the need for endotracheal intubation and prolonged use of muscle relaxants and sedatives, and permits an early reduction in oxygen concentrations, thus minimizing the hazard of pulmonary oxygen toxicity," Dr. Shyamal K. Sanyal told a recent meeting here of the American Lung Association.

All the children (six months to 14 years of age) had progressive bilateral

alveolar disease caused by Pneumocystis carinii infection, with respiratory distress and, in all but one case, fever, reported Dr. Sanyal, who is Director of the Intensive Care Unit and Chief of the cardiopulmonary disease service at St. Jude's Children's Research Hospital in Memphis.

O₂ Given to All

"Either pentamidine isethionate or trimethoprim-sulfamethoxazole as well as chlorpheniramine, intravenous fluids, and oxygen were administered to all patients," he added.

As respiratory distress progressed, the patients were placed "in an Emerson tank respirator without bellows, and hooked up to a source of continuous negative pressure," Dr. Sanyal said in an interview. With this pressure constantly applied outwardly, "the response

IN CONSULTATION

What's New and Important About Serum Alpha₁-Antitrypsin in Man?



The Consultant

RICHARD C. TALAMO, M.D.
Chief, Division of Immunology, Department of Pediatrics
Johns Hopkins University School of Medicine
Baltimore, Md.

IN 12 YEARS since Laurell and Erikson first described a strong association between severe alpha₁-antitrypsin deficiency and chronic obstructive pulmonary disease of unusually early onset. Ten years ago, Fagerhol and Laurell first recognized the genetic heterogeneity of the alpha₁-antitrypsin; currently, well over 10 different alleles for alpha₁-antitrypsin have been described. These alleles

appear to regulate the serum level of the protein, as well as its electrophoretic mobility. The system of alpha₁-antitrypsin alleles is termed the Pi system (protease inhibitor). Normal individuals are of Pi type M, and those with severe deficiency are of Pi type Z. The latter have a slow-moving alpha₁-antitrypsin on electrophoresis, in contrast to only 10-20% of normal. Several recent studies have demonstrated that alpha₁-antitrypsin is stored in a granular molecular form in discrete bodies in the liver cell cytoplasm of Pi type Z individuals.

The striking high frequency of carriers of the Pi type Z gene (2.5% of most populations) means that 1/1600 to 1/4000 individuals is homozygous for Pi type Z. Clinical correlates of Pi type Z include infantile liver disease, often progressing to cirrhosis, the onset of pulmonary emphysema in young adults, or, rarely, a combination of these. Very recent studies suggest that the structural difference between Pi type Z and Pi type M alpha₁-antitrypsin may result from one or two simple amino acid substitutions.

What is the source of serum alpha₁-antitrypsin in man and what determines the amount and circulatory properties of this protein?

Serum alpha₁-antitrypsin is synthesized in the liver cell and rapidly secreted into serum in the normal, Pi type M individual. Pi type Z alpha₁-antitrypsin is made in the liver cell, partially secreted into serum in very low amounts, and excessively stored in the liver cell cytoplasm. The circulating levels and electrophoretic mobility of alpha₁-antitrypsin are determined by the genetics of the protein. In addition, a variety of drugs (estrogens, for example) and non-specific inflammatory states can induce an increased rate of synthesis of alpha₁-antitrypsin by the liver, resulting in elevated circulating levels of the protein.

What clinical entities are associated with a deficiency of alpha₁-antitrypsin?

Hereditary alpha₁-antitrypsin deficiency may be associated with liver disease beginning in infancy, with pulmonary emphysema beginning in young adults, or, rarely, with a combination of the two diseases in childhood. In addition, serum alpha₁-antitrypsin

deficiency is characteristic of infants with the respiratory distress syndrome. This is not on a genetic basis, and is accompanied by deposits of alpha₁-antitrypsin in the alveolar hyaline membranes.

Does the degree of deficiency of alpha₁-antitrypsin affect the type of clinical entity that develops?

Yes, as noted above, severe alpha₁-

antitrypsin deficiency of Pi type Z is clearly associated with lung and/or liver disease. The carrier state, Pi type MZ, may be associated with lung or liver disease in occasional patients, but does not clearly predispose an individual to clinical disease of any kind. However, it has been documented that lung function in Pi type MZ individuals deteriorates more rapidly with age than it does in a normal Pi type M person.

Is there any type of treatment that can be used to alter this condition once it has been recognized?

There is currently no specific means of elevating genetically low alpha₁-antitrypsin levels. It would be impractical at the present time to consider replacement with normal human alpha₁-antitrypsin, since the half-life of the protein in the circulation is only four to six days. General principles of comprehensive clinical care for pulmonary and/or liver disease should be applied. Prohibition of smoking is an important adjunct to the treatment of Pi type Z individuals, once the condition has been recognized, since smoking has definitely been shown to hasten the pulmonary damage in the disease. It is hoped that synthetic enzyme inhibitors will become available for the treatment of this condition some day.

Pediatrician Finds Early Snuggling To Mother Is Good for Neonates

Medical Tribune Report

ST. LOUIS—Babies who spend the first 45 minutes of life snuggled skin-to-skin against their mothers have less chance of early infection, more weight gain in the first year, and a longer period of breastfeeding than infants who are separated from their mothers during the first 24 hours, Dr. John Kennell said here.

Addressing a subspecialty session at the American Pediatric Society meeting, Dr. Kennell, Professor of Pediatrics at Case Western Reserve University Medical School, Cleveland, also reported on a related study of 60 mother-infant pairs, which revealed that "those mothers given early contact were significantly more affectionate with their babies than the delayed contact or the control mothers."

Both studies, he said, suggest that "close contact for the mother and her infant during the first minutes and hours after birth may be crucial for the formation of a strong attachment," which greatly influences the child's health. The studies also support previous findings that there is a sensitive period "when both mother and infant appear to be highly aroused."

The present findings, he added, "help to define the short duration of the sensitive period and emphasize that just 45 minutes of early contact may have more profound effects than we previously appreciated. These findings compel the reconsideration of hospital practices that even briefly separate mother and infant," he stressed.

Dr. Kennell's research team, including Dr. Marshall Klaus, also Professor of Pediatrics at Case, based their findings on 40 mother-infant pairs at the Social Security Hospital in Guatemala.

"The 20 control mothers were separated from their infants from the time of delivery until the first feeding at 24 hours, as is routine at this hospital," he said.

"The 20 early-contact mothers... spent 45 minutes after the episiotomy repair, alone, skin-to-skin, in a private room with their undressed infants under a heated panel where they were encouraged to breast feed." Other than this, care of mothers and infants was identical, he added, with free powdered milk available to all during the first year.

Follow-up visits at one, three, six, nine, and 12 months showed that "the infants whose mothers had early contact gained significantly more weight... and also had fewer infections," Dr. Kennell reported. In addition, while all were breastfeeding at the time of discharge, "the percentage of early contact mothers who were still breastfeeding was significantly greater than the control group at six and 12 months (19% vs. 104 days)."

To investigate the duration of the "sensitive period," the research team took a fourth sample of 60 primiparous Guatemalan mothers and divided them into three groups: early contact (immediately after birth), delayed contact (after 12 hours), and control contact (after 24 hours). By carefully observing mother-infant interaction 36 hours after birth, researchers scored the mothers on specific points of affectionate behavior (e.g., talking, fondling, kissing, smiling, face-to-face contact) during the first 15 seconds of each minute for 15 minutes. Again, the early-contact mothers were significantly more affectionate with their babies than the other two groups.

Next In Consultation

DR. JOHN F. GRIFFITH, Professor and Chairman, Department of Pediatrics, University of Tennessee Center for Health Sciences, and Medical Director, Le Bonheur Children's Hospital, Memphis, Tenn., will discuss "slow virus" infections in children, whether administration of live-virus vaccines to infants may result in an increase in subacute sclerosing panencephalitis, the pathogenesis of herpes simplex virus infections, treatment of "slow" virus infections, and signs of such infections that a general practitioner should look for.

Early Trial Finds Dicyclomine Eases Signs of Achalasia

Medical Tribune Report

MIAMI BEACH—An oral anticholinergic agent has relieved the symptoms of achalasia in an early controlled trial, a Temple University team has reported.

Difficulties in swallowing solids and liquids were "significantly improved," and such symptoms as regurgitation and vomiting were relieved to a lesser extent, in almost all patients who received dicyclomine HCl orally or subcutaneously in the course of a 14-week, double-blind crossover study, the team told the American Gastroenterological Association.

The findings point to the possibility of a useful role for anticholinergic therapy in symptomatic achalasia, and warrant larger controlled trials and follow-up studies, said Dr. Ira F. Lobis, Temple Research Fellow.

The study was prompted by the observation that anticholinergic drugs inhibit the activity of both gastric and cholinergic stimuli at the level of the lower esophageal sphincter (LES), Dr. Lobis explained. Since achalasia is attributed to functional obstruction of the distal esophagus produced by an abnormal LES, he said, it seemed useful to try a pharmacologic approach, prior to conventional mechanical procedures to treat the disorder.

Ten patients with achalasia were entered in the study and the effect of dicyclomine on their LES pressures was measured aurally to establish baseline data. The patients were then randomized into a blind crossover trial, with dicyclomine 20 mg or placebo administered for four weeks, followed by crossover therapy for four weeks, no treatment for two weeks, and resumption of therapy for an additional four weeks.

After subcutaneous administration of the anticholinergic, LES pressures dropped maximally from a basal level of 44 to 25.4 mm Hg, and after oral administration the pressures dropped from 41.9 to 28.5 mm Hg, Dr. Lobis reported.

In an interview, Dr. Lobis stressed that anticholinergic therapy is not designed to, replace conventional methods, but "may reduce symptoms long enough to delay surgery, and may have a valuable role in the overall therapy of patients with achalasia." Coauthor was Dr. R. S. Fisher.

Scottish & Newcastle
Seltone GB Ltd.
Seltone Healthcare
Shear & Phipps
Smith & Phipps
Somerville & Phipps
Sony United Kingdom
Stival Ltd.
Stratford-Up-Avon
Tale & Lyle Sugars
Telford Foods Ltd.
Telford Foods Ltd.
Tesco Stores Ltd.

"packaging"
other exhibi
opportunit
to meet
not avail
chance to
discussio
new idea
Kevin Hyde
Wella Gase

The Docks
The Chees
The Invest
The Kery
The Ryl
The Walle
Thornston
Thornston
Tomy U
Tovall H
Trailor
Traville
Treats
Tulip
Vitam
W A
W Jo
Well
Wes
WHL
WHL
WHL

ager

Purchasing

Purchasing
Management
Buyer
Manager
Supply Chain Manager
Director

Py
ents Ltd
e
ar Mortlake Road

Tumor-Specific Antigen Aids Recovery from Lung Cancer

Continued from page 1

of cancer with important implications for immunodiagnosis and immunotherapy."

The clinicians report that of 26 lung cancer patients treated post-surgically with immunotherapy or immunotherapy plus chemotherapy all are alive and 24 are disease-free, half of them for more than 21 months. Among a control group of 23 patients treated by standard means, six have died.

The new factor in the treatment strategy is an allogeneic, tumor-specific antigen, developed and prepared by Dr. Hollinshead in Washington and used clinically by Dr. Stewart in Ottawa. Despite the modest number of patients and the preliminary nature of the study, the investigators are cautiously hopeful that their work will lead to a better prognosis for lung cancer patients, 40-50% of whom now die from recurrent disease within two years after surgery, they told MEDICAL TRIBUNE in an interview.

Beginning of New Era

Dr. Stewart and Dr. Hollinshead, who have been collaborating in the project since 1969, see their achievement as the beginning of a new era in the treatment of all types of tumors. "We admit that this is a very small series, but we do feel that the preliminary results suggest the immunotherapy approach might well be applicable to other tumor systems," Dr. Stewart said.

After surgery, Drs. Stewart and Harris treated each patient who received immunotherapy with methotrexate, then "rescued" the patient from the toxicity of the massive dose of MTX with citrovorum factor. The procedure is repeated 30 days and 60 days later. Seven to nine days after each course of MTX and citrovorum factor, the patient receives an IM injection of tumor antigen, derived from tumor cells of the same histologic type as his own combined with Freund's complete adjuvant. Each of the three doses contains between .521 mg and 1 mg of antigen, depending on the patient and the availability of antigen, for a total of about 1.5 mg.

Dr. Stewart believes that the chemotherapy and immunization enhance each other's effectiveness, and plotted his clinical strategy to make the most of this synergistic interaction.

'Rebound Overshoot'

Methotrexate suppresses the ability of the bone marrow to produce lymphocytes. "After rescue with citrovorum factor, however, the immune system not only recovers, it comes back even stronger than before," said Dr. Harris, who calls the phenomenon "rebound overshoot." At this point, the tumor antigen is given in order to equip the new army of lymphocytes, recruited by the methotrexate, with weapons specifically lethal to tumor cells.

The patients tolerated the vaccine well, although all of them developed ulcers at the vaccination site, most of which became infected. Staphylococcus aureus caused most of the infections, which responded well to antibiotics and healed completely within 12 months. In seven patients, high fever (up to 40° C) followed the second injection of the vaccine. The fever lasted less than 30 hours and required no treatment beyond bed rest and aspirin.

The investigators emphasized that their work, which they presented at the recent meeting of the American Society of Clinical Oncologists in Toronto, is still experimental and cannot at present be applied to large numbers of patients. The sheer logistics involved complicate the picture further.

Continued in the next issue



In her lab at George Washington University Medical Center, Ariel C. Hollinshead, Ph.D., elected "Medical Woman of the Year" for her "pioneer work," adjusts microconcentrators during final purification of lung cancer vaccine.

The ultimate objective test: sleep laboratory proof of effectiveness... now in geriatric insomnia patients

Six female insomniacs, ranging in age from 67 to 82 years, received Dalmane (flurazepam HCl) for seven consecutive nights in the sleep research laboratory. Improvement over pre-treatment baseline levels was significant for sleep induction and sleep maintenance ($p < .05$). And the greater the sleep problem in these patients, the better the effect with Dalmane (significant correlation at $p < .01$ level).



'Liver Attack' in Frenchmen Held Nonexistent

Continued from page 2

These disturbances, lasting from a few days to two or three days, may be caused by such factors as alcoholic excess or food intolerance—but the liver is blamed. It is also blamed for digestive lesions.

Dr. Beahmou also pointed out that there is an extreme tendency to blame the liver for symptoms as diverse as cutaneous eruptions, isolated fevers, or any digestive disorder, all of which are irrelevant in hepatic

pathology. A systematic exploration of the liver and bile ducts in patients with these symptoms reveals no anomaly, even with the most sensitive tests. And patients suffering from renal illness of the liver, associated with a major deterioration of hepatic functions, such as chronic hepatitis or certain cirrhoses, never complain of these symptoms so widely attributed to the liver.

In many cases the precise cause of the patient's "liver ailment" may be detected. Migraine headaches, for example, are related to a vasomotor phenomenon, not the liver, and they may be associated with vomiting, frequently the primary symptom. Their treatment, particularly with ergotamine derivatives, is often very effective—but this has nothing to do with the liver.


Right subcostal pains may be related to many different causes, such as chole-

lithiasis, duodenal ulcer, or colic. Similarly, intolerance to certain foods is often accompanied by digestive reactions, such as nausea, vomiting, diarrhea—the origin of which is gastric and intestinal, not hepatic.

It may happen that the origin of the symptoms remains unknown, said the French hepatologists, but there is too much hassle on the part of patients and physicians to blame the liver without proof. The abuse of medications is often habitual in such patients, leading to iatrogenic pathology. Cessation of drug taking alone may lead to a spectacular regression of the "liver attack" in a substantial number of cases.

The "liver attack," said Prof. Dhumeaux, is a convenient diagnosis, with which the patient is readily satisfied even though the real cause of the symptoms may then be ignored.

Insomniacs sleep faster, longer



Results expand and confirm objective proof of efficacy in younger adults with insomnia

The effectiveness of Dalmane (flurazepam HCl) was demonstrated in earlier studies of younger adults with trouble sleeping, staying asleep or waking long enough. On average, these studies, Dalmane induced sleep within 17 minutes and allowed 7 to 8 hours of sleep, at the same time reducing number of nighttime awakenings.

Relative safety, even in patients on warfarin

Morning "hang-over" has been rarely reported with Dalmane. And no unacceptable changes in prothrombin time were reported in warfarin patients on Dalmane. The usual dosage is 30 mg i.s.; in elderly and debilitated patients, initial dosage is 15 mg to preclude oversedation.

Before prescribing Dalmane (flurazepam HCl), please consult complete product information, a summary of which follows: Indications: Effective in all types of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening; in patients with recurring insomnia or poor sleeping habits; and in acute or chronic medical situations requiring restful sleep. Since insomnia is often transient and intermittent, prolonged administration is generally not necessary or recommended. Contraindications: Known hypersensitivity to flurazepam HCl.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. Caution against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Use in women who are or may become pregnant only when potential benefits have been weighed against possible hazards. Not recommended for use in persons under 15 years of age. Though physical and psychological dependence have not been reported on recommended doses, use caution in administering to adult chronic individuals or those who might increase dosage.

Precautions: In elderly and debilitated, initial dosages should be limited to 15 mg to preclude oversedation, dizziness and/or ataxia. If combined with other drugs having hypnotic or CNS depressant effects, consider potential additive effects. Empty usual precautions in patients who are severely depressed, or with latent depression or suicidal tendencies. Periodic blood counts and liver and kidney function tests are advised during repeated therapy. Observe usual precautions in presence of impaired renal or hepatic function. Adverse Reactions: Dizziness, drowsiness, light-headedness, staggering, ataxia and

falling have occurred, particularly in elderly or debilitated patients. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdose, have been reported. Also reported were headache, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, GI pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and GI complaints. There have also been rare occurrences of leukopenia, granulocytopenia, sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations, and elevated SGOT, SGPT, total and direct bilirubins and alkaline phosphatase. Paradoxical reactions, e.g., excitement, stimulation and hyperactivity, have also been reported in rare instances.

Dosage: Individualize for maximum beneficial effect. Adults: 30 mg usual dosage; 15 mg may suffice in some patients. Elderly or debilitated patients: 15 mg initially until response is determined. Supplied: Capsules containing 15 mg or 30 mg flurazepam HCl.

REFERENCES

1. First JF Jr: Data on file, Medical Department, Hoffmann-La Roche Inc., Nutley NJ
2. Data on file, Medical Department, Hoffmann-La Roche Inc., Nutley NJ
3. Robinson DS, Amidon EL: Interaction of benzodiazepines with warfarin in man. In: The Benzodiazepines, edited by Garattini S, Mussini E, Randolf LO, New York, Raven Press, 1973, p. 641

New evidence proves insomnia relief in elderly patients

Dalmane
(flurazepam HCl) ©

One 15-mg capsule i.s.—initial dosage for elderly or debilitated patients.
One 30-mg capsule i.s.—usual adult dosage.
15 mg may suffice in some patients.

For all common types of insomnia:

ROCHE
ROCHE LABORATORIES
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

from Britain

MDs Advised to Look for Scurvy in 'Gout' Patients

Continued from page 2

treatment, it is arguable as to what extent maintaining normal uric acid levels will help renal function.

In the case of asymptomatic hyperuricaemia, now more commonly seen since the advent of autoanalyses, his advice is not to rush into treatment.

With serum uric acid levels of 8-8.9 mg per 100 ml, only about 25% of men turn out to have gout. This proportion jumps to 90% with serum uric acid levels of more than 9.0 mg %.

The risks to be considered when faced with a patient with asymptomatic hyperuricaemia are gout (which is nothing to worry about till the first symptoms appear), renal damage, and ischaemic heart disease.

Little is known about the likelihood of an asymptomatic hyperuricaemic patient developing either renal impairment or ischaemic heart disease.

A mild renal impairment is common in gout patients but it is a case of which is the cart and which the horse. There is, of course, the possibility of uric acid stones, Dr. Scott concluded.

from Japan

Protection Urged For Fingertips of Isotope Workers

Continued from page 2

For 13 weeks without protection, thereby exceeding the maximum digital exposure tolerance dose of 20 rems.

More recently, a questionnaire circulated among some members—those over 40 years of age—of the Society of Medicoradiation and the Society of Clinical Radiation Technicians disclosed smooth fingertips and other anomalies in 24% of the physician group and 17% of the technicians. A follow-up study of fingerprints in 102 responding physicians showed 3.9% to have a greater number of wrinkles and shallower furrows than normal fingerprints (see photo).

In radiologic practice, acute disorders due to exposure rarely occur, Dr. Koga said. The commonly encountered disorders seem to be those that develop more slowly: cutaneous atrophy, leukemia, cancer, cataracts, premature aging, and shortened life expectancy.

Back in 1970, it was estimated that only about 0.3% of medical, paramedical and dental personnel in Japan were occupationally exposed to more than 5 rads, Dr. Koga said. Although this figure has remained more or less unchanged over the intervening years, there is some evidence that the actual exposure level may be higher.

Dr. Koga concluded that hands and fingertips may be especially vulnerable to possible radiation hazards, particularly with the increasing clinical use of isotopes, such as 99mTc, which have a short half-life period.

Scottish & Newcastle
Sollatop GB Ltd
Solon Healthcare Co
Shenker Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerfield Stores
Sony United Kingdom
St Ivel Ltd
Stratford-Up-Avon
Tate & Lyle Sugars
Taunton Cider Sigs
Telford Foods Ltd
Tesco Stores Ltd

"packaging"
other exhibi
opportunit
to meet
not availa
chance to
discuss
new ideas
Kevin Hyde
Wells Gra

The Boots
The Chester
The Inver
The Kony
The New
The Ryth
The Well
Thomson
Thomson
Tommy L
Tovall
Trellis
Treats
Trebor
Tullip
Vilam
W A
W Jo
Wes
Wh
Wh
Wh

The Regal

Purchasing

Purchasing
Department Manager
Buyer
Manager
Supply Chain Manager
Director

by
ants Ltd
er Mortlake Road

Ismelin® sulfate
(guanethidine sulfate)

Esmil®
guanethidine monosulfate 10 mg
hydrochlorothiazide 25 mg

WARNING
This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy directed to the individual patient. If the fixed combination represents the dosage as determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be reevaluated as conditions in each patient warrant.

INDICATIONS
Ismelin
Moderate and severe hypertension either alone or as an adjunct.
Esmil
Hypertension. (See box warning above.)
CONTRAINDICATIONS
Guanethidine: Known or suspected pheochromocytoma; hypersensitivity; frank congestive heart failure not due to hypertension; use of MAO inhibitors. Hydrochlorothiazide: Anuria; hypersensitivity to thiazide or related diuretic drugs. The routine use of diuretics in an otherwise healthy pregnant woman with or without mild edema is contraindicated and possibly hazardous.
WARNINGS
Antihypertensives are potent drugs and can lead to disturbing and serious clinical problems. Physicians should be familiar with all drugs and combinations before prescribing, and patients should be warned not to deviate from instructions.
Guanethidine
Warn patients about the potential hazard of orthostatic hypotension, which can occur frequently and is most marked in the morning and is accentuated by hot weather, alcohol, or exercise. To help prevent falling, warn patients to sit or lie down with onset of dizziness or weakness, which may be particularly bothersome during the initial period of dosage adjustment and with postural changes. The potential occurrence of these symptoms may require alteration of previous daily activity. Caution patients to avoid sudden or prolonged standing or exercise while taking the drug.

Concurrent use with rauwolfia derivatives may cause excessive postural hypotension, bradycardia, and mental depression. If possible, withdraw therapy 2 weeks prior to surgery to reduce the possibility of vascular collapse and cardiac arrest during anesthesia. If emergency surgery is indicated, administer preanesthetic and anesthetic agents cautiously in reduced dosage and have oxygen, atropine, vasopressors, and IV solutions ready for immediate use to treat vascular collapse. Vasopressors should be used with extreme caution in patients on guanethidine because of the possibility of augmented response and the greater propensity for cardiac arrhythmias. Dosage requirements may be reduced in presence of fever. Exercise special care when treating patients with a history of bronchial asthma, since their condition may be aggravated.

Hydrochlorothiazide
Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte imbalance may precipitate hepatic coma. Thiazides may be additive or potentiative of the action of other antihypertensive drugs. Potential occurs with ganglionic or peripheral adrenergic blocking drugs. Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy
Guanethidine: The safety of guanethidine for use in pregnancy has not been established; therefore, this drug should be used in pregnant patients only when, in the judgment of the physician, its use is deemed essential to the welfare of the patient.
Hydrochlorothiazide: Usage of thiazides in women of childbearing age requires that the potential benefits of the drug be weighed against the possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers
Thiazides cross the placental barrier and appear in cord blood and breast milk.
PRECAUTIONS
Discontinue the effects of guanethidine are cumulative over long periods. Initial doses should be small and increased gradually. Use very cautiously in hypertensive patients with renal disease and nitrogen retention. Do not give guanethidine to patients with severe renal disease or renal insufficiency or moderate to severe renal disease with azotemia. Do not give guanethidine to patients with severe renal disease or renal insufficiency or moderate to severe renal disease with azotemia. Do not give guanethidine to patients with severe renal disease or renal insufficiency or moderate to severe renal disease with azotemia.

patients with severe cardiac failure and not with extreme caution. In incident cardiac decompensation, weight gain or edema may be avoided by the administration of a thiazide. Remember that both digitalis and guanethidine slow the heart rate. Peptic ulcers or other chronic disorders may be aggravated by a relative increase in parasympathetic tone. Amphetamine-like compounds, stimulants (eg, epinephrine, norepinephrine, isoproterenol, sympathomimetic amines, and sympathomimetic amines), and sympathomimetic amines (eg, epinephrine, norepinephrine, isoproterenol, sympathomimetic amines, and sympathomimetic amines).

mine) and other psychopharmacologic agents (eg, phenothiazines and related compounds), and oral contraceptives may reduce the hypotensive effect of guanethidine. Discontinue MAO inhibitors for at least one week before starting guanethidine. **Hydrochlorothiazide**: Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. Observe patients for clinical signs of fluid or electrolyte imbalance (hypotension, hypochloremic alkalosis, and hypokalemia). Serum and

urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbance such as nausea or vomiting. Hypokalemia may develop with thiazides as with any other potent diuretic, especially during brief diuresis, when

severe cramps are present, or during concomitant administration of steroids or ACTH. Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia especially with reference to myocardial activity. Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbance of renal function may occur in edematous patients

in moderate hypertension.

...most patients tolerate guanethidine with minimal side effects when dosage adjustment is carefully managed.

1. Freis ED: *The Modern Management of Hypertension*, US Government Printing Office, 1973, pp 13, 14.

Currently, there is a positive trend towards reevaluating Ismelin (guanethidine) for use in moderate hypertension. Perhaps the most effective antihypertensive available, Ismelin offers convenient, once-a-day dosage— a major factor in encouraging patient compliance. And, when given in moderated dosage, guanethidine does not appear to present a major side effect problem. When Ismelin is added to other antihypertensives, initial doses should

be small and increased gradually by small increments. Once blood pressure control is achieved, all drug dosages should be reduced to lowest effective level, often minimizing side effects. Patients should be warned about the possibility of orthostatic hypotension and cautioned to avoid sudden or prolonged standing or exercise. Please turn page for further opinion in treating moderate hypertension.

Doctors are rediscovering...
once-a-day
Ismelin®
(guanethidine)

low weather, appropriate therapy is withheld rather than administration of salt. In rare instances when the hypotensive is life-threatening, replacement is the therapy of choice. Thiazide drugs may increase the responsiveness to hypotension. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. Thiazides may cause arterial responsiveness to decrease in a few patients on prolonged thiazide therapy. Hypotension may occur or frank

collapse may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration. Thiazide drugs may increase the responsiveness to hypotension. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. Thiazides may cause arterial responsiveness to decrease in a few patients on prolonged thiazide therapy. Hypotension may occur or frank

collapse may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration. Thiazide drugs may increase the responsiveness to hypotension. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. Thiazides may cause arterial responsiveness to decrease in a few patients on prolonged thiazide therapy. Hypotension may occur or frank

collapse may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration. Thiazide drugs may increase the responsiveness to hypotension. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. Thiazides may cause arterial responsiveness to decrease in a few patients on prolonged thiazide therapy. Hypotension may occur or frank

collapse may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration. Thiazide drugs may increase the responsiveness to hypotension. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. Thiazides may cause arterial responsiveness to decrease in a few patients on prolonged thiazide therapy. Hypotension may occur or frank

CIBA

guanethidine monosulfate 10 mg
hydrochlorothiazide 25 mg

Esimil[®], the once-a-day alternative to methyldopa plus hydrochlorothiazide

● Gunneridine and the other alkaloids were both effective and relatively well tolerated when administered with linzole. During the treatment of the additional 10 patients, the dose of gunneridine was reduced to 100 mg daily.

Doctors are reconsidering the advantages of treating moderate hypertension by allowing to remain on

peresthesias, headache, xanthopsia. **Dermatologic/Hypersensitivity**—pruritus, photosensitivity, rash, urticaria, bronchial angitis, Stevens-Johnson syndrome, and other hypersensitivity reactions. **Endocrine**—hypokalemia, agranulocytosis, thrombocytopenia, aplastic anemia, and/or low orthostatic hypotension may occur and may be potentiated by alcohol, barbiturates, or narcotics. **Other**—hypertension, muscle pain, weakness, rash/edema. Whenever severe reactions are moderate or severe, reduce dosage or withdraw therapy.

DOSEAGE AND ADMINISTRATION

HOW SUPPLIED
 Tablets, 10 mg (pale yellow, scored)
 and 25 mg (white, unscored)

30, 60, 100 and 1000

Esimil
Tablets (white, scored), each containing 10 mg guanethidine monosulfate and 26 mg hydrochlorothiazide; bottles of 50, 60 and 100.

Chas. Pfizer & Co. Inc.
Division of Ciba-Geigy Corp.
Summit, New Jersey 07901

References
1. Fraile ED. *The Modern Management*

2. Terpely EL: Controlled trial of guanethidine and methylodopa in moderate hypertension. *Curr Ther Res* 16:1187-1195, 1974.
3. Niaz AS: Adverse reactions and interactions limiting the use of antihypertensive drugs. *Am J Med* 58:495-503, 1975.
4. Briggs AH, Holland WC: The cardiovascular system. *Antihypertensive drugs*. In DiPalma RJ (ed): *Drugs in Pharmacology in Medicine*. New York, McGraw-Hill Book Co, 1971, pp 853-888.
5. Langford HG: Hypertension. In Conn

HF (ed): *Current Therapy* 1973, Philadelphia, The WB Saunders Co, 1973, p 201.

6. Glazer N: Comparison of auroethidine and methyldopa in essential hypertension: A controlled study. *Curr Ther Res* 17:243-256, 1975.

2/1981 17

C I B A

C I B A

Wednesday, August 4, 1976



lysis unit is staffed around clock by a pediatric ne-
 rologist and two RNs. On duty here (l. to r.): Sheryl
 Melber, Children's Hospital, Detroit; Lilz Aglipay, Mt.
 Sinai Hospital, N.Y.C.; Dr. George Schwartz, Einstein.

Only Camping Program For Children on Dialysis Now in Its Second Year


YOUNGSTERS with kidney failure can be like "other kids" and go off to summer camp at a facility equipped with a four-bed dialysis unit at Frost Valley YMCA camp in Olliville, N.Y. Opened last year and so far the only one of its kind, the camp operates as a satellite of the Hospital of the Albert Einstein College of Medicine in New York. Dr. Ira Griefner, Director of Pediatrics and of the Children's Kidney Center of the Hospital, says the innovative program enables children aged 7 to 16 on maintenance dialysis to enjoy a two-week normal camping experience unavailable before.



Horseback riding ranks high among the favorite outdoor activities available during the eight-week program, which has an enrollment this summer of 32 children.



Each child undergoes dialysis three times a week, with the four- to five-hour procedure fitted as unobtrusively as possible into the schedule of camp-life activities and social contacts.



Hours on dialysis seem shorter with a friend around. This year, program has added a week for children under 7 with their parents.



Companionship with others having the same disease—and similar problems—is big plus for many alcohol patients who usually meet each other only in hospital or clinic setting.

Julien Gorst Project Director
John McKee Project Manager
Vicki Morison Administration Manager
Isebel Hutchings Conference Manager
Charlotte Banton-Hughes Conference
Kerry Brown Technical Services

TW9 2LS

1 332 2422
1 332 0939

Microsurgery Successful in Testis Autotransplant

Medical Tribune Report

PHILADELPHIA—In what is believed to be the first successful operation of its kind, an intra-abdominal testis in a nine-year-old boy has been transplanted to the scrotum using a microvascular surgical technique, a San Francisco urologist reported here. "Al-

though the long-term results regarding fertility will not be known for many years, the immediate results appear good," Dr. Sherman J. Silber told a seminar of the International Society of Pediatric Urologists.

"No testicular atrophy is detectable on palpation," Dr. Silber said. "Good

pulsation was noted immediately in the spermatic artery, and venous drainage was excellent. Without microvascular orchidopexy, the testis would have been removed or allowed to remain in the abdomen, where an occult neoplasm might have developed. With our technique, a viable testis was preserved in a position favorable for future observation."

Reversed Vasectomies

Dr. Silber, who last year reported a 60% success rate in a new microsurgical technique for reversing vasectomies (MT, Nov. 19, 1975), is Associate Professor of Urology at the University of California, San Francisco, and Chief of Urology at the Veterans Administration Hospital there. His associate and coauthor both in the vasectomy reversals and in this testicular autotransplant has been Dr. Justin Kelly, of Royal Children's Hospital, Melbourne, Australia.

"One to 5% of cryptorchid testes are intra-abdominal and cannot be properly brought down into the scrotum by conventional methods," Dr. Silber said. "In such cases, necessary division of the spermatic vessels results in risk of testicular ischemia. We at-

tempted to solve this problem by microanastomosis of the spermatic vessels to the inferior epigastric vessels in the groin." The autotransplant procedure not only allowed tension-free placement of the high testis, originally located just below the kidneys, into the scrotum, but also provided an adequate blood supply.

This experience with testicular autotransplantation suggests that the microsurgical technique may be applicable in the transplantation of testes from one individual to another, Dr. Silber told MEDICAL TRIBUNE. "Now that it's been shown that the blood vessels can be rejoined, and that reversal of vasectomy has been perfected—these are the only three hook-ups you need—it is going to be very easy to transplant a human testicle and preserve its function."

"One indication would be where the male is infertile and his religious beliefs prohibit artificial insemination," he said, adding that this may apply to Moslems and Orthodox Jews.

"Another indication would be for a man who lost his testes in an accident or was born anorchid, who might seek a transplant instead of going on male hormones for the rest of his life."

"This is an interesting speculation—but it hasn't been done yet," Dr. Silber concluded.

In all patients, Dr. Cohen noted, successful treatment of the underlying heart disease led to improved or normal liver function tests.

"Pericardial necrosis has been described in hypotension, shock and low cardiac output states associated with myocardial infarction," Dr. Cohen concluded. "It probably results from hypoxic damage. We are now reporting an identical lesion presenting clinically as hepatitis. This lesion is presumably due to clinically unrecognized low cardiac output states in these five patients without hypotension or right-sided congestive heart failure and is potentially reversible." Coauthor was Dr. M. M. Kaplan.

produce hypoglycemia, renal failure or pain at the site of injection, Dr. John Landis, principal investigator and Associate Director of Medical Services, the Medical Center of Western Massachusetts, noted in an interview.

The sole patient with a negative lavage who died did not have evidence of pneumocystis at autopsy.

Procedure 'Very Safe'

Later employed in over 100 patients and normal volunteers, bronchofiberscopic pulmonary lavage proved to be a "very safe procedure," Dr. Kelley continued. The two major risk factors encountered were hypoxemia and thrombocytopenia, but neither were considered contraindications. Seven hypoxic patients received supplemental oxygen during the procedure. In five thrombocytopenic patients, no bleeding episodes occurred during bronchoscopy. Two patients receiving ventilatory support via nasotracheal tube prior to bronchoscopy and 100% oxygen during the procedure died of bacterial superinfection unrelated to respiratory support at least seven days after pulmonary lavage.

documented in one patient by echocardiogram and in another by cardiac catheterization. In the first case, that of a 61-year-old man with atherosclerotic coronary artery disease, echocardiography was performed "because of the strong clinical impression that this patient's heart disease was not severe enough to cause the liver disease," Dr. Cohen said. The patient had been admitted with a six-week history of anorexia, fatigue and a 12-pound weight loss. But he was not hypotensive and had no signs of congestive failure, Dr. Cohen stressed. Echocar-

diography, however, revealed "poor myocardial contractility and a very low systolic ejection fraction of 15%."

In the second patient, a woman with rheumatic heart disease, cardiac catheterization for evaluation of increasing exertional dyspnea had been delayed because of unexplained high transaminase levels. When the procedure was ultimately performed it revealed a normal right atrial pressure, a "strikingly low cardiac index of 1.4 and critical mitral stenosis." After mitral valve replacement, the transaminase levels rapidly returned to normal.

Pulmonary Lavage Method May Replace Lung Biopsy

Medical Tribune Report


NEW ORLEANS—Bronchofiberscopic subsegmental pulmonary lavage is a safe and accurate means of evaluating immunosuppressed patients suspected of having pneumocystis pneumonia—the most common cause of diffuse pulmonary infiltrates in such patients—and may preclude the need for open lung biopsy, Dr. Jason Kelley, a Pulmonary Fellow at the University of Vermont, told the American Thoracic Association.

Other low morbidity diagnostic methods, such as bronchial brushing, percutaneous needle biopsy or aspiration, and endobronchial forceps biopsy have yielded a "significant number of false negative results," Dr. Kelley said. When findings are negative in the face of a strong diagnostic presumption, physicians have had to weigh whether to expose immunosuppressed patients, who are frequently physiologically unstable, to the anes-

thetic and surgical risks of open lung biopsy or institute empiric drug therapy, he stated.

Since pulmonary lavage specifically samples the alveolar space, where pneumocystis disease occurs, the technique was employed, following initial animal studies, on a trial basis in 15 patients in whom progressive pneumonia and fever suggested pneumocystis or other opportunistic pathogens. Three proved to have pneumocystis by lavage, and 12 showing negative results had either leukemic infiltrates, bacterial pneumonia, viral pneumonia, connective tissue disease or chemotherapy-induced fibrosis, confirmed by tissue diagnosis, bronchoscopic culture or response to altered chemotherapy.

"We were not compelled to perform open lung biopsy in any case," Dr. Kelley reported, and no patient with a negative lavage received pentamidine, the current drug of choice for treating pneumocystis infection. The drug may



Abdominal testis, left, was severed from vena cava and aorta, placed in scrotum, right, and attached to inferior epigastric artery and saphenous vein.

Low Cardiac Output May Resemble Hepatitis

By NATHAN HORWITZ

Medical Tribune Staff

MIAMI BEACH—A lesion that presents clinically as hepatitis but is, in fact, due to low cardiac output stemming from left-sided heart failure, was described here by a Boston team.

The syndrome, which occurs without pulmonary congestion, may not be uncommon in patients with low cardiac output, the investigators suggested.

The new entity was identified in five individuals who had neither hypotension nor right-sided congestive heart failure—well-documented links to overt liver disease, said Dr. J. A. Cohen of the New England Medical Center Hospital.

Hepatitis was initially suspected in the five patients because of anorexia, nausea, and fatigue in two cases, and "striking" unexplained transaminase elevations in three, Dr. Cohen told the American Association for the Study of Liver Diseases. Each of the patients had a history of heart disease, but an experienced cardiologist described each, after examination, "as well compensated and without signs of congestive failure." And, said Dr. Cohen, "The cardiologist concluded that the liver dysfunction was unrelated to the heart disease."

Decrease Documented

Liver biopsy in all patients revealed central liver necrosis, but in none was there histologic evidence of hepatitis or of passive congestion. The hepatitis surface antigen was negative in the three patients in whom it was tested; the investigator continued. There was no neck vein distension in the group, and peripheral and central venous pressures were normal.

Decreased cardiac output was then

New Camera Enables Bedside Nuclear Scan

Medical Tribune Report

DALLAS—A newly developed portable nuclear scanning camera allows radiologic procedures to be brought to the bedside of critically ill patients, Dr. John A. Burdine, Professor of Nuclear Medicine, Baylor College of Medicine in Houston, reported here. The new Low Energy Mobile (LEM) camera was unveiled during the Society of Nuclear Medicine's annual meeting.

Dr. Burdine conducted clinical trials with the LEM over a four-month period involving 150 patients in St. Luke's Episcopal and Texas Children's Hospitals in Houston.

He found that the camera increases diagnostic capabilities without compromising patient safety and comfort. He predicted that the unit will probably receive wide acceptance in cardiology, pediatrics, and orthopedics, where movement of the patient may be undesirable.

"While the usefulness of nuclear imaging procedures in the care of the critically ill is well understood, many of these patients are confined to cir-



Low Energy Mobile portable nuclear camera, developed by the radiographic division of G.D. Searle & Co., allows all routine radiologic procedures to be performed at bedside, reducing patient movement and discomfort to a minimum.

cumstances where they cannot be transported to the nuclear medicine laboratory," Dr. Burdine said.

"With LEM, virtually all routine nuclear imaging procedures utilizing low energy radiopharmaceuticals may be

performed at the patient's bedside." The LEM camera, made by the radiographic division of G.D. Searle & Co., weighs 790 lbs., has a 250 kilo electron volt energy limit, and can do 80% of a standard camera's work.

Effect of Irradiation in Cancer: An Issue at Radium Society

Medical Tribune World Service

VANCOUVER, B.C.—The controversy regarding the clinical and prognostic significance of immunosuppression in irradiated cancer patients received wide attention here at the Fifty-Eighth Annual Meeting of the American Radium Society.

Does radiation therapy itself cause significant suppression of cell-mediated immunity? Yes and no, implied Dr. Charles McKhann, Professor of Surgery at the University of Minnesota. His studies of 150 melanoma and sarcoma patients show that they already had depressed immune responses, as measured both by T-cell rosette formation and by phytohemagglutinin (PHA) lymphocyte stimulation.

But this immunologic depression is intensified by current treatment modalities, Dr. McKhann said. Surgery, or possibly the anesthesia used with it, dampens cell-mediated immunity for a matter of days, and chemotherapy for weeks or months. Irradiation, he said, appears to dampen it for years.

Tests Too Sensitive?

Yet the clinical significance of such findings is not clear, Dr. McKhann pointed out. "We see T-cell depression in normal persons with a cold." Perhaps the T-cell rosette formation and PHA lymphocyte stimulation tests are "too sensitive." There are different subpopulations of T-cells, but it is not known which is "protective." In any event, investigators "don't know exactly" what their findings mean.

The need for more definitive data was also cited by Dr. William M. Wara, Assistant Professor of Radiation Oncology, University of California, San Francisco, who reviewed the pertinent scientific literature.

The "most controversial report" in the literature to date, Dr. Wara said,

is that of Dr. Jan Stjernswärd (*Lancet* 1:1352, 1972), who attributed depressed cell-mediated immunity in breast cancer patients to irradiation of the thymus. This interpretation has "recently been challenged" by other investigators who have not only questioned "the statistical validity" and "follow-up time" of Dr. Stjernswärd's studies, but also "demonstrated that inclusion of the thymus gland in the irradiated field was not a prerequisite for subsequent immunosuppression."

Immunosuppression in irradiated patients has now been well documented, Dr. Wara said, but he agreed with Dr.

McKhann that its significance "remains unclear." Accordingly, Dr. Wara raised two questions which he felt would serve to clarify the clinical issues in radiation therapy for neoplastic disease: "Is depressed T-cell immunity as evaluated in vitro related to patient prognosis and survival? And can this immunosuppression be altered by immunotherapy?"

"Clearly," he concluded, "prospective controlled trials must be initiated to evaluate the effects of localized irradiation on lymphocyte subpopulations, as well as the effect of immunotherapy (BCG, transfer factor, levamisole, thymosin, etc.) on these patients. Only with these studies will we be able to determine the length and prognostic significance of immunosuppression caused by irradiation."

Partial Cystectomy Proves Useful in Some Bladder Ca

Medical Tribune Report

LAS VEGAS—Partial cystectomy may be equally as effective as total cystectomy in treating primary and secondary carcinoma of the bladder, a Cleveland Clinic team told a meeting of the American Urological Association.

Advocates of partial cystectomy cite its advantages: technical simplicity, diminished morbidity and mortality rates, and preservation of continence and potency. Proponents of radical surgery argue that partial cystectomy represents less than adequate treatment in terms of survival and ultimate cure rate, Dr. Andrew C. Novick explained.

Fifty patients underwent partial cystectomy as the primary means of treatment in the period from 1960 to 1972. The five-year survival rate was 67% for Stage O-A, 53% for Stage B, and 20% for Stages C and D1 combined, which compares "most favorably" with total cystectomy outcomes, according to Dr. Novick and Dr. Bruce H. Stewart, of the Department of Urology.

Dr. Novick added that patients in whom free margins of resection were accom-


plished for unifocal disease achieved longer survival with less chance of developing recurrent bladder cancer.

12-Year Study

The 12-year study involved 43 males and seven females, with an average age of 64 years, who underwent partial cystectomy at the Cleveland Clinic and included all tumor types, Dr. Novick said. He added that during this period an additional 12 patients underwent partial cystectomy as adjunctive surgical treatment for primary gastrointestinal or gynecologic malignancies secondarily invading the bladder. Less favorable results were reported for this group of patients.

Patients with primary bladder carcinoma were considered for partial cystectomy under the following conditions: where tumors were confined to the bladder dome; tumors within a bladder diverticulum; solitary tumors overlying a ureteral orifice and/or involving the distal ureter; tumors not amenable to transurethral resection; and tumors in poor-risk patients.

Patients with primary bladder carcinoma were considered for partial cystectomy under the following conditions: where tumors were confined to the bladder dome; tumors within a bladder diverticulum; solitary tumors overlying a ureteral orifice and/or involving the distal ureter; tumors not amenable to transurethral resection; and tumors in poor-risk patients.



Splenectomy Risks?

... presenting excerpts from current journal articles and commentaries of interest to physicians who treat children.


"How can one reduce the risks [of infection] in patients with a valid indication for splenectomy? When possible, splenectomy in infants should be deferred. When it seems essential in children under five, it should be followed by prophylactic oral penicillin for at least three years. This practice might be extended to older children and adults with an immunological defect. Vaccination with polyvalent pneumococcal vaccine has been suggested but has not been submitted to trial. Subcutaneous implantation of splenic tissue prevents serious infection in splenectomized rats and has been suggested for application in man." This would be inappropriate in Hodgkin's disease or chronic granulocytic leukaemia, and the number of patients in whom this technique might have a place is likely to be small. Where possible, damaged spleens should be repaired rather than removed. Unnecessary splenectomy incidental to intra-abdominal surgery in some large series is responsible for up to 30% of all splenectomies. In malarious zones, splenectomized patients should go onto malaria-suppressive drugs immediately and for life. The long-term hazards of splenectomy would be reduced if all concerned—doctors, patients, and patients' parents—became aware of the urgent need for treatment when infection arises." (*Editorial, The Lancet* 1:1168, May 29, 1976)

Correcting Immunodeficiency

"... Owing to the laws governing the inheritance of the major histocompatibility antigens... a majority of infants [with severe combined immunodeficiency] will have no compatible potential donors [of bone marrow for transplantation]. The repeated dramatic reversal of the uniformly fatal prognosis in the disorder by grafts of compatible marrow cells over the past eight years has prompted the intensive search for alternative forms of definitive therapy when no histocompatible donors exist; with few exceptions, these efforts have been unsuccessful. In [our studies of] two unrelated male infants... fresh, very young fetal liver cells were used in attempted immunologic correction of the adenosine deaminase positive form of severe combined immunodeficiency. The observation of transient graft-versus-host disease in both infants documents the graft-versus-host potential of even this very young fetal tissue. More importantly, the successful immunologic reversal of the immunodeficiency in one of the infants confirms the usefulness of fetal liver cells as an alternative form of definitive therapy when bone-marrow transplantation cannot be performed." (*Rebecca H. Buckley, et al; New Engl. J. Med.* 294:1076, May 13, 1976)

Julien Gerst Project Manager
John McKee Project Manager
Vicki Morrison Administration Manager
Isabel Hutchings Conference Secretary
Charlotte Benton-Hughes

Surrey TW9 2LS
Tel: 081 332 2422
Fax: 081 332 0939



China: Trees and Art, Technology and Ecology

I HAVE COMMENTED on Allan Chase's observations on the medical ecologic bi-centennial of Sir Percival Pott's observation on coal soot, the cause of scrotal cancer in chimney sweeps. Our discussion ranged much wider. We agreed on the fallacies and dangers of neo-Malthusian doctrines; we wondered at the marvel of our industrial nation producing enough food both for ourselves and for scores of millions around the world with just 4% of our own population. Our discussion turned to the ability of the People's Republic of China to feed almost a quarter of the world's population, about three-quarters of a billion souls, sans our technology or mechanization.

I have long been interested in the archaeology and art of China and fascinated with their discoveries preceding those of the West in technology and in aesthetics. One has to see, to fully enjoy and believe, the solutions that Chinese painters achieved several hundred years before Cézanne, the Impressionists and even the Expressionists. Knowing of my interests, Allan couldn't resist telling me about a recent experience of his own.

Recurrent Theme

His sister and her husband had just returned from China. As he had suggested to them, they recorded the events of the day each evening. Allan had the opportunity of listening to the tapes in a few sittings. He noted a recurrent theme—again and again reference to the planting of trees, to the dispersal of factories, plants of small size sited in relation to an agricultural commune. It appeared that in contrast to the West which introduced the technology of the Industrial Revolution, there may be a difference in approach to mass production in today's China. Even as large-scale facilities are being built, as for manufacture of steel or generation of hydroelectric power, the Chinese appear to be significantly decentralizing and fostering small-scale manufacturing enterprises. The implications inherent in massive reforestation and in industrial decentralization raise many fascinating conjectures.

Admiration of Nature

With respect to reforestation, there has been extensive mobilization of the population ever since the Chinese communist revolution. The floods of China have constituted an historic tragedy with recurring devastation and disruption, disease and death. But can it not be that the reforestation of China is much more than just flood control? Have the Chinese leaders, consciously or unconsciously, mobilized men, women and children to the task of harnessing solar energy through the medium of chlorophyll and storing it in their forests?

I have long been sensitive to the Chinese admiration of nature, to their fascination with landscape. Their pictorial presentations relating to the phys-

ical and aesthetic qualities of bamboo had brought much of their painting close to my heart and awakened a passionate love of the esthetic of Chinese calligraphy.

The Chinese philosophy, the way of thinking implicit in Chinese art, Chinese absorption with the multifaceted aspects of nature as reflected in the interweaving of multiple forms and themes into their iconography, may carry over in some measure to their approach to science and technology. Their art and poetry would quickly reveal the very pointed pleasure they derive from actions with a complex of significances. This may be true also for reforestation with its aesthetic effects on the landscape, its practical application as in flood control, its other pragmatic advantages in the creation and storage of natural resources and, come to think of it, even its biochemical benefits in ecologic terms—the conversion of carbon dioxide into oxygen.

Balanced Biosphere

The concept of life cycle and that of a balanced biosphere goes back millennia in China. It well reflects their realism and their empiric solutions which have contributed so much to the Chinese understanding and positive use of nature. Han ceramics recorded social customs at the time of Christ and one of them shows a piggy bank on a "balanced sty" rather than a "balanced aquarium." The pig ate "night soil" and the pig in turn was eaten. Night soil was also used to fertilize the fields whose bean sprouts and vegetables were so important a part of the Chinese diet. The cycle of food reflected a cycle of life.

Allan pointed out in relation to the dispersion of factories another interesting gain—the dilution of potential pollutants. As in so much of Chinese custom and action, we must go beyond a simplistic unitary motivation and even beyond the potential military implications: placing small factories in relation to agricultural communities is both time- and material-saving. Commuting to work, so much a part of the urbanized, industrialized western societies, is reduced if not eliminated. The physical state of the worker is improved by walking or pedaling a bicycle rather than by the application of the gas pedal of a car. Decentralization contributes more than a saving of time and the benefits of physical exercise. It reduces


the waste of metals and fuel consumed and toxic pollutants produced by cars, buses and trains.

True Progress of Man

We can't avoid making comparisons and we must stress the danger of unidimensional thinking. It is high time we stopped looking at the problems of the world solely in terms of population numbers. With one-quarter of the population of China, our industrial plant can produce multiples of the environmental pollutants they do. Worse than that, we have replaced the biological benefits of man's excreta with the non-biodegradable and highly toxic "excreta" of an industrial society which can poison not only its soil and water but its people as well. Nature is remarkable—if we do not tortuously distort its cycle, as we unnecessarily do by unthinking industrialization. An automobile created by man pollutes. The natural by-products of man's man, properly used, enriches. It cannot be that the Chinese will stand alone in recognizing that nature affords us a closed system in which man can physically as well as intellectually and spiritually live well, even as he enriches his world. There is nothing in our philosophy and there is much in our history which says that we, too, can meet the challenge and assure that industrial and technologic progress is tied, in more of its aspects, to the true progress of man.

Medicine on Stamps

Oliver Wolcott



Oliver Wolcott (1726-1797) was born in Windsor, Conn. Shortly after graduating from Yale, he was commissioned in the militia and served in the "King George's War." He then studied medicine as an apprentice to his brother. His medical career was rather limited, since he served as Army Surgeon only during the campaign against Burgoyne in 1775. He remained in public service for the rest of his life. In 1776 he was elected to the Continental Congress and is pictured in the above stamp as one of the signers of the Declaration of Independence. He is the 41st member from the left. He was elected Governor of Conn. in 1796 and served until his death. The nation's Bicentennial coincides with the 250th anniversary of his birth.

From Dr. Joseph Kler
Stamp: Minkus Publications, Inc., New York

EDITORIAL CAPSULES

... brief summaries of editorials or comments in current medical and scientific journals.

Need for Holistic Medicine

"The inability of physicians, psychiatrists included, to practice a genuinely holistic medicine that integrates knowledge of the body, the mind, and the environment is striking. Psychiatrists, for example, tend to adhere to one or another of the various ideologies in their field and to ignore the others; in spite of advances in neurochemistry and genetics, these disciplines often get little attention from psychiatric practitioners or training programs. Nonpsychiatrist physicians mainly interested in disease or dysfunction of a particular organ-system ignore the unaffected systems and the psyche.

"These attitudes persist despite pages of polemics about the importance of treating the whole person, and despite overwhelming evidence that a comprehensive understanding of man requires a general systems approach.

"Medicine must be an adaptive system of learning. Just as we expect people to be mature and effectively coping individuals, we must have the courage and the determination to study the forces that produce and maintain health and well-being, not merely the forces that produce disease.

"A failure to explore and counter the forces that sustain these dualistic splits will permit them to retard the development of a general systems approach by discouraging the transfer of information from neurophysiology to psychoanalysis, from small group and family dynamics experience to general practice, from neurochemistry to clinical psychiatry, from the social and behavioral sciences to general medicine, and so on and on. Pertinent knowledge will remain in the hands of the researchers and the universities and have virtually no impact at all on the physician and his practice. Under these conditions, medicine will see still further lowering of its status in the public eye. Our dissatisfied or unsatisfied clientele will search elsewhere, leaving us open to the charge that we are more interested in protecting our traditions than helping our patients.

"Breaking the grip of these dualities will permit medicine to recapture the whole person as the focus of attention and reduce those dehumanizing preoccupations with the disease alone, the psychosomatic, the liver or the pancreas alone, the psychosis alone. This is holistic medicine for a society that needs to learn from the medical profession how to be an effectively caring society." (Editorial, Roy W. Menninger, M.D., *Ann. Int. Med.* 84:604, May, 1976)

EPIGRAMS—Clinical and Otherwise

Not know that what disturbs our blood
Is but its longing for the tomb.
William Butler Yeats
(1865-1939)
The Wheel

Sitting pretty for years to come...

Gentle in bringing patients down to normotensive levels, Esidrix will continue to "sit right" with many of the mild hypertensives for whom you prescribe it. Indeed, it can mean years and years of even, uneventful control.

Esidrix. It is still unsurpassed as a basic diuretic/antihypertensive.

And many patients with edema rarely need a more potent diuretic.

Contraindications include anuria. Use cautiously in patients with impaired renal or hepatic function.



Esidrix®
(hydrochlorothiazide)
for year-after-year control
of mild hypertension

Esidrix® (hydrochlorothiazide)

INDICATIONS
Hypertension and edema.

CONTRAINDICATIONS
Acute hypersensitivity to this or other sulfonamide-derived drugs. The routine use of diuretics in otherwise healthy pregnant women with or without mild edema is contraindicated and possibly hazardous.

WARNINGS
Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may be additive or potentiative of the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy
Thiazides in women of childbearing age require that the potential benefits of the drug be weighed against its possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers
Thiazides cross the placental barrier and appear in cord blood and breast milk.

PRECAUTIONS
Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. Observe patients for clinical signs of fluid or electrolyte imbalance (hyponatremia, hypochloremic alkalosis, and hypokalemia). Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbance such as nausea or vomiting.

Hypokalemia may develop with thiazides as with any other potent diuretic, especially during brisk diuresis, when severe cirrhosis is present, or during concomitant administration of corticosteroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Occasional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than administration of salt, except in rare instances when the hy-

ponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Transient elevations in plasma calcium may occur in patients receiving thiazides, particularly in those with hyperparathyroidism. Pathological changes in the parathyroid gland have been reported in a few patients on prolonged thiazide therapy.

Hypuricemia may occur or frank gout may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration. Thiazide drugs may increase the responsiveness to tubocurarine. The antihypertensive effects of the drug may be enhanced in the post-sympathetomy patient. Thiazides may decrease arterial responsiveness to norepinephrine. This is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

If nitrogen retention indicates onset of progressive renal impairment, consider withholding or discontinuing diuretic therapy.

Thiazides may decrease serum PBI levels without effects of thyroid disturbance.

ADVERSE REACTIONS
Gastrointestinal—nausea, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestasis), necrotic enterocolitis (infantile), pancreatitis, vertigo, parosmia, headache, xanthopsia, dermatologic—photosensitivity—purpura, photosensitivity, rash, urticaria, necrotizing angitis, Stevens-Johnson syndrome, and other hypersensitivity reactions.

Hematologic—leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. Cardiovascular—orthostatic hypotension may occur and may be potentiated by alcohol, barbiturates, or narcotics. Other—hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness. Whenever adverse reactions are moderate or severe, reduce dosage or withdraw therapy.

DOSEAGE
Individualize dosage by titrating for maximum therapeutic response at the lowest possible dose. Hypertension (mild)—Usual dose 75 mg daily. Maintenance—After a week dosage may be adjusted downward to as little as 25 mg or upward to as much as 100 mg daily. Combined therapy—When necessary, other antihypertensives may be added gradually and with caution because of the potentiating effect of this drug. Dosages of ganglionic blockers should be halved. Edema: Initial—25 to 50 mg daily for several days. Maintenance—25 to 100 mg daily or intermittently. Refractory patients may require up to 200 mg daily.

SUPPLIED
Tablets, 50 mg (yellow, scored); bottles of 30, 60, 100, 1000, 5000, and Accu-Pak blister units of 100. Tablets, 25 mg (pink, scored); bottles of 30, 60, 100, 1000 and 5000.

Consult complete literature before prescribing. CIBA Pharmaceutical Company, Division of CIBA-GEIGY Corporation, Summit, New Jersey 07901.

C I B A

Julien Gort Project Director
John McKee Project Manager
Vicki Morison Administration Manager
Isabel Hutchings Conference Manager
Charlotte Benton-Hughes Conference Asst
Services Manager

Richmond
Surrey TW9 2LS
Tel: 081 332 2422
Fax: 081 332 0939

Scottish & Newcastle
Solihull GB Ltd.
Sofon Healthcare Group
Sheaffer Pen (UK) Ltd.
Smith & Nephew
SmithKline Beecham
Somerset Stores
Sony United Kingdom
St Ives Ltd.
Stratford Upon-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhib
opportunit
to meet
not availa
chance to
discussin
new ide
Kevin Hyde
Wells Gros

The Boots Co
The Cheese
The Inver
The Kery
The New C
The Nyl
The Wello
Thornl
Thornl
Tomy UK
Tovell Ho
Trallor
Tranl
Treats C
Trahor
Tulip In
Vitame
W A Tu
W Jac
Walla
Wadl
Whit
Whit
Wick
Woo

ing
sing
at Manager
ayer
for
Main Manager
ector

rtlake Road

Harvard Community Brewing 'Genetic Engineering' Storm

Continued from page 3

"It's a cooling off period so that the council can hear evidence in a non-crisis situation," Mr. Pat Centanni, assistant to the Mayor, told MEDICAL TRIBUNE. "After that, we'll see."

The Harvard situation promises not to be an isolated incident but on augury of the future. A resolution before the Energy and Environment Committee of the U.S. Conference of Mayors proposes that investigators planning to perform any recombinant DNA research first notify the mayor and the legislative body of the community of their intentions. The resolution's sponsor? Mayor Alfred E. Vellucci, of Cambridge.

The public and political furor which threatens to engulf recombinant research distresses many scientists. They point out that all investigations have attendant risks. The impact of recombinant technology on society was a focal point of a recent Miles Laboratory-sponsored symposium held at MIT. MEDICAL TRIBUNE spoke with some of the participants.

No 'Fail-Safe' Research

"Recombinant DNA is a subset of a larger category of work," said geneticist Seymour Lederberg, Ph.D., of Brown University, Providence, R.I. "We've been working with animal DNA and viral DNA for roughly a generation. And in many cases recombinant DNA is safer to work with."

"Much of the time, we're working with a fraction of the viral genome and deliberately so. The overall impact of recombinant research may in many cases be to reduce risks," he told MEDICAL TRIBUNE.

"Take the example of producing vaccines against viral illness. We now have a crash program to produce a vaccine against swine influenza. To make the vaccine, large volumes of the virus must first be manufactured."

"If we had the gene for the protein coat of influenza virus—that's the only thing we actually need to produce the vaccine, it could be incorporated into E. coli. The bacterial cell would then make the influenza protein we're interested in. It wouldn't make the virus itself," he explained.

"I don't mean to minimize the hazards of DNA research. There's no such thing as fail-safe research. Despite the safeguards and the guidelines which have been set up, I'm assuming there will be human mistakes. It's plausible," he continued.

"But there's a trade-off. If we're so concerned about possible dangers, we might seriously consider expunging hospitals from cities. After all, they're a focal point of contagious and dangerous illness. But that's not very realistic, is it?"

Some critics argue that the information resulting from recombinant experiments could be obtained other ways.

"Well, yes and no," said Roy Curtiss, III, Ph.D., of the University of Alabama, Birmingham. "In some areas, for example in purifying eukaryotic genes, we don't have another way of extracting the information. In other areas, it's a judgmental opinion. Another technique might take longer,

involve greater expense and give potentially less resolution.

'Accelerated Knowledge'

"In my own field, recombinant technology has accelerated our knowledge of replication of information in microorganisms. Certainly it could have been obtained by other methods. But with recombinant research we've learned three to four years worth of information about E. coli in only one year," he explained.

"It's going to be up to the investigator to make a decision whether recombinant DNA is the best approach," said Stanley Falkow, Ph.D., of the University of Washington in Seattle. "And despite all the indications we have, very likely this research will not be particularly hazardous."

Dr. Falkow believes that the "biggest biohazard is likely to be ignorance" of good laboratory technique among the investigators and their staff. Dr. Curtiss agrees.

"The probability of a catastrophic occurrence is minuscule where one uses a disarmed host-vector system, that is, a strain of bacteria which has been so weakened that it cannot survive outside of laboratory conditions," Dr. Curtiss told MEDICAL TRIBUNE. (He has developed two such strains of E. coli, labeled 1776 and 1876 in honor of the nation's bicentennial. "We're working on 1976," he said.) "Of course, the probability figures in no way factor in human error, ranging from sloppy technique to mistakes in judgment."

"There is a tendency for people doing this research to be molecular biologists and biochemists without a great deal of training in microbiology or microbiological techniques," Dr. Falkow notes. "It's surprising how much basic microbiology they don't know," echoes Dr. Curtiss. "We've had dealings with a lot of labs wanting to use our strains. But they can't get the bug to grow or transform."

As a remedy, basic courses in microbiological technique are being conducted at the University of Minnesota, Cold Spring Harbor, and at NIH facilities, according to Dr. Falkow.

Talk of 'Monsters'

Dr. Lederberg, for one, however, believes that the press, with its talk of "monsters" escaping from the laboratory, has oversold the dangers of recombinant DNA research to the public. "The most notorious aspect of a story becomes the most glamorous," he says, a thought seconded by Dr. Stanley Cohen, of Stanford University.

"The news media with its emphasis on all or nothing research is laboring under a misconception," Dr. Cohen told MEDICAL TRIBUNE. "Everyone agrees that certain experiments should not be carried out. But I don't know one responsible scientist who wants to see this research halted."

Dr. Cohen is quick to point out that it was the researchers themselves who first noted the hazards of recombinant research and to a fairly drastic, although not unprecedented, move, declared a voluntary moratorium on some experiments while guidelines for



Dr. George Wald, Nobel prize winner (1967) in physiology and medicine and Higgins Professor of Biology at Harvard, testifies at public hearing of Cambridge, Mass., City Council, held to consider granting Harvard permission to build a high-security lab where recombinant DNA research would be carried out.

future investigations were promulgated. The now legendary Asilomar Conference in February, 1975, classified experiments according to risk (banning some for the present), set laboratory standards for each category, and indicated appropriate host-vector systems to be used.

Revised and expanded, these recommendations form the basis of the NIH guidelines on recombinant DNA research issued at the end of June. Scientists expect that the guidelines, which apply only to NIH-funded research, will also be accepted by private laboratories here and investigators abroad.

However, the controversy may not be over technical safety so much as ethical considerations, suggested Dr. Curtiss, a view shared by Dr. Roland F. Beers, Jr., of Miles Laboratories.

Coronary Artery Aneurysm: Less Rare Than Suspected?

Medical Tribune Report

PHILADELPHIA—Eleven new cases of coronary artery aneurysms, bringing to 34 the world's known total of this disorder, were reported here by a University of Iowa team.

Suggesting that the condition may be more common than is now suspected, Dr. Herman L. Falsetti said the Iowa series was identified in a population of 742 patients who were referred for cardiac catheterization and coronary arteriography from July, 1973 to April, 1975.

The prospective study showed the clinical picture in patients with coronary aneurysms to be similar to that of severe coronary artery disease, diagnosis being possible only by coronary arteriography, Dr. Falsetti told the American College of Physicians.

The 11 patients in the series, including 10 men and one woman, ranged in age from 35 through 69 and had had symptoms from one month to 14 years. Five patients had had previous myocardial infarctions.

In 10 of the 11 patients, the coronary artery aneurysms were multiple and associated with extensive coronary

atherosclerosis. Left ventricular function was impaired when measured by end-diastolic pressure, end-diastolic volume and ejection fraction, the investigator said. Segmental left ventricular pressure contractions were "severely abnormal."

"There is no significant difference in the distribution of aneurysms between those thought to be atherosclerotic or those due to congenital or other malformations," he observed. "In general those due to trauma or mycotic in nature are often single. Those secondary to inflammatory disease, such as polyarteritis or atherosclerosis, are multiple. To be emphasized, however, is that the presence of one coronary artery aneurysm should lead to the suspicion of others in the heart as well as other parts of the body."

Seven patients in the Iowa series and eight in the published reports underwent surgery, Dr. Falsetti noted. Thirteen were alive in the immediate postoperative period, and of our seven patients all are still alive and have had improvement in their symptoms," Dr. Falsetti is Professor of Medicine at the University of Iowa.

"I GOT LOST— LOST IN MY OWN NEIGHBORHOOD"

Yesterday I was going to the grocery store and suddenly I didn't know the way. I was all mixed up... I thought it was the old neighborhood. It frightened me—and it's not the first time. My children say it's my second childhood. Well it's not. I took care of my kids. Please, doctor...

WHEN "GRAY AREA" SYMPTOMS START TO AFFECT THE ELDERLY PATIENT'S LIFE

A SINGLE 1-mg HYDERGINE SUBLINGUAL TABLET THREE TIMES A DAY.

- Meets the proper 3-mg total daily dose of Hydergine therapy.
- Makes compliance easier for patients who might be confused by more complicated schedules.
- Helps assure optimal dosage because of better adherence to dosage regimen.
- Oval shape of 1-mg tablet makes it easier for the elderly patient to identify.

Contraindications: Hypersensitivity to the drug. **Precautions:** Because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing Hydergine sublingual tablets.

Adverse Reactions: Serious side effects have not been found. Some sublingual irritation, transient nausea, and gastric disturbances have been reported. Hydergine sublingual tablets do not possess the vasoconstrictor properties of natural ergot alkaloids.

Dosage and Administration: 1 mg sublingually three times daily. Alleviation of symptoms is usually gradual and results may not be observed for 3-4 weeks.



GIVE ENOUGH, SOON ENOUGH
LONG ENOUGH

HYDERGINE 1mg Sublingual Tablets

Each 1-mg Hydergine sublingual tablet contains dihydroergocornine 0.333 mg, dihydroergocristine 0.333 mg, and dihydroergokryptine 0.333 mg, as the mesylates, representing a total of 1.0 mg.

SANDOZ PHARMACEUTICALS, EAST HANOVER, NEW JERSEY 07936



Scottish & Newcastle
Selleys GB Ltd
Soton Healthcare Group
Sheaffer Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerville Stores
Sony United Kingdom
St Ivel Ltd
Stratford-Upon-Avon
Tate & Lyle Sugars
Taunton Cides plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhibi
opportunity
to meet. M
not availab
chance to
discussing
new ideas
Kevin Hyde,
Wella Groat

The Boots Com
The Cheese Co
The Invergo
The Korrygo
The New Cov
The Ryvita Co
The Wollco
Thornsons P
Thornsons P
Tomy UK Lt
Tovall Heal
Trallord Po
Tranfield
Treats Gm
Trebort B
Tullip Inter
Vhameal
W A Turn
W Jordan
Wella Gm
Westler
White A
Whitwo
Wickes
Woolw

Interview Probes Decision to Immunize All

Continued from page 1

other medications, and the usefulness of other available agents, such as antibiotics and amantadine, in curtailing the ravages of an epidemic.

In discussing the reasoning behind the planned utilization of 200 million doses of the monovalent vaccine and 20 million doses of combined swine and Victoria vaccines for high-risk persons, Dr. Cooper told Dr. Sackler that "the entire population is susceptible to infection."

Stockpiling Discarded

And because a flu epidemic "can spread like fire," the HEW Assistant Secretary for Health said the stockpiling option was discarded. Too much time would elapse between a given outbreak and activation of a vaccination program, he stressed.

Asked why, then, the government could not move as quickly in clearing drugs against such other problems as cardiovascular disease and high blood pressure, Dr. Cooper cited "differences between biologicals and other forms of pharmaceuticals."

Dr. Cooper specified, for example, that "the information we have regarding toxicity and effectiveness of other influenza vaccines developed and used in recent years is generally applicable to this vaccine." Furthermore, he said, "the swine flu threat is considered imminent, and there is no other way to prevent the potential morbidity and mortality..." On the other hand, noted Dr. Cooper, cardiovascular drug treatments "are already available covering such drug class and each disease factor. The basis of approval for each type of therapeutic agent must rest on sound scientific principles and substantial evidence of safety and effectiveness... as required by the Food, Drug and Cosmetic Act."

The HEW official conceded that "although prevention is the only way to curb high morbidity and mortality from influenza... antibiotic therapy [is] very important." Antibiotics "will almost certainly be employed," he said, though in some cases this therapy may be "too late" or "insufficient."

Considering the hypothetical pro-

tection against viruses offered by massive doses of ascorbic acid, the availability of amantadine—a drug with antiviral effects, and the unpredictability concerning an epidemic, wouldn't it be as logical, Dr. Sackler asked, to support such measures as to support the program?

"The value of massive doses of vita-



The first injection of experimental swine flu vaccine went into Dr. Harry Meyer, Director of FDA's Bureau of Biologics. Preparing to give the shot is HEW's Assistant Secretary for Health, Dr. Theodore Canner.

mins still remains to be established [and] expert opinion still does not consider amantadine a replacement for the vaccine," replied Dr. Cooper.

In the next issue: Dr. Cooper discusses the results of clinical trials with the swine-type vaccine, the possible need for a damage compensation mechanism, and the reliance on "past experience" for chronic toxicity data.

Dr. Comfort Urges Caution in Prescribing Drugs for Elderly

Medical Tribune Report

LOS ANGELES—Drugs can and do play a key role in helping the older man or woman cope with the fears, anxieties, depressions and psychoses that accompany advancing age, Dr. Alex Comfort told a meeting of the American Geriatrics Society here. However, the gerontological expert warned, the physician must be sure that the elderly patient's emotional and psychiatric disturbances have not been brought on or exacerbated by overmedication.

"The prescription of any drug, even aspirin, is no light matter," Dr. Comfort said. "Old people go crazy because they were crazy when they were young, because they are ill, or because we drive them crazy. Many older patients are overmedicated with drugs they have bought themselves over the counter or which have been prescribed by doctors. In many cases, old people are just simply zonked out."

Plastic Bag Therapy

When treating an elderly patient, the physician's most important tool may be a plastic bag, Dr. Comfort counseled. "The bag should be given to the patient or to his family to collect all the medications the patient is taking. Sometimes a very large bag is necessary because the patient may be taking as many as 20 or 30 different medications."

Once the patient has been weaned of his vast supply of drugs, a proper assault on the patient's problems may begin. According to Dr. Comfort, successful control of psychiatric and emotional disturbances can be achieved with treatment that includes counseling, occupational and recreational activities—and a well-controlled drug regimen.

Depression, for example, will respond to any of several drugs, including tricyclics, methylphenidate, phenel-

zine, and tranlycypromine, Dr. Comfort said. "Methylphenidate should be used in small amounts or you'll send your patient up the wall. Phenelzine could be used for depressions marked by obsessions and tranlycypromine might be worth trying before ECT."

ECT, Dr. Comfort said, if cautiously but adequately used, could be useful against depressions, especially those marked by suicide threats. "And," Dr. Comfort added, "Don't be afraid to talk to the patient about suicide. You won't cause it... And you may prevent it."

The elderly hypochondriac will also respond to proper treatment. "The last thing the hypochondriac needs," Dr. Comfort cautioned, "is a detailed explanation that his disease is psychosomatic."

Moreover, the hypochondriac should not be subjected to a series of needless surgeries meant to placate or, worse, to punish. "Don't approach with the philosophy that 'if the old bat thinks she has cancer then, by God, let's do a bronchoscopy and show her,'" Dr. Comfort said.

Proper treatment for the hypochondriac includes adequate observation, a prescription for an inert, mildly unpleasant placebo, and a follow-up appointment in two or three weeks.

To treat paranoia adequately, Dr. Comfort said, the physician must learn to distinguish between the real thing and well-founded anger. "Old people," Dr. Comfort said, "do have a tough road in our culture and not every complaint is paranoia."

One hint: "In most cases, the paranoia relates to domestic matters. It's not that the Nazis are out to get him, but that someone is stealing the mail—meaning that they forgot to mail letters or to write—or that people are always throwing dirt into the laundry—mean-

ing that they forgot to turn on the washing machine."

Once paranoia has been adequately diagnosed, Dr. Comfort said, a major tranquilizer, administered in low doses and in liquid form, may very well alleviate feelings of persecution and discrimination. "But be sure to give the tranquilizer in a liquid form," Dr. Comfort emphasized. "Paranoids have a thing about pills. They think people try to poison them with pills and will usually just hide them behind their dentures and spit them out later."

Ventilating Anxieties

The acute and chronic anxieties that are brought on by moves or other changes in the environment respond well to simple crisis intervention. "Help the patient ventilate his or her anxieties," Dr. Comfort suggested. "Help them relearn the environment."

Because older people worry about changes in their sleeping patterns, they should also be taught that with advancing age, sleep requirements and sleep habits change. "In old age, stage three sleep is short and sleep, generally, is lighter," Dr. Comfort said. "Reassure the patient that the new sleeping patterns, including daytime catnaps, are normal. Milk-based hot drinks are effective in helping the patient sleep."

Sleeplessness brought on by agitated depression, mania, or by acute anxieties, Dr. Comfort added, can be treated for two or three days with tricyclics, a major sedative or a nonbarbiturate hypnotic.

When the patient is burdened by so-called nursing home disease—a disturbance marked by blunting, regression, depression, and pseudodementia—therapy is often effective. Because the syndrome is triggered when the patient loses his job, is abandoned by his family or is treated as incompetent, Dr. Comfort said, it can be alleviated by giving the patient an adequate personal and social environment. "The patient can and does recover if real social responsibilities are imposed," Dr. Com-

fort said. "But the patient should not be over-supported."

Often, Dr. Comfort said, nursing home disease is mistaken for chronic brain syndrome. True chronic brain syndrome can be diagnosed by—among other things—testing the patient's ability to carry out sequential tasks. Chronic brain syndrome, Dr. Comfort said, can be reversed with drugs. But the best treatment, he added, may be the treatment which, given earlier in life, prevents the onset of the syndrome. Effective treatment of hypertension may be one way of preventing the later appearance of the syndrome.

Elderly people, Dr. Comfort summarized, will respond to proper medical approach. But the doctor must avoid the "false assumption" that the aging process inescapably renders men and women nasty, asexual and incompetent.

"We must also avoid iatrogenic disease," Dr. Comfort emphasized. "Drugs should be used fearlessly if indicated. But they should not be prescribed in large numbers and they should be reviewed periodically."



© 1976, Medical Tribune, Inc.

Dr. Cooper Explains Rationale Behind Swine-Type Flu Shots

Continued from page 1

Was the one death at Fort Dix enough to trigger a national vaccination program?

I should like to stress that the judgment to go forward with a national immunization program was not based solely on the finding of one death at Fort Dix. The dominant reason was that a significantly different flu virus had shown up in an influenza outbreak and had been involved in person-to-person transmission of the disease.

Historically, whenever the influenza virus has undergone a major antigenic shift, and caused a limited outbreak, a major epidemic has followed. In this case, the swine virus has not been identified in person-to-person transmission of the disease for many years. Therefore, virtually the entire population is susceptible to infection.

There is developing debate as to whether the government overreacted. How sure are we that we are going to have an influenza epidemic this year?

I believe we had no choice as public officials but to take the action we did to protect the public health, even though we do not know for sure that there will actually be an epidemic of influenza this fall or winter caused by the swine-type virus now designated as A/New Jersey/76. The decision does show that the government can act with dispatch when it needs to protect health.

Didn't the government have the option of preparing the vaccine, stockpiling it and/or using it in high risk groups?

We considered this option only but discarded it; an influenza epidemic can spread like fire. It would take 10 to 13 weeks from the time we had notice of further swine influenza outbreaks to activate an immunization program, motivate the public to participate, and give the shots. Then it would take two or three additional weeks after vaccination for antibodies to build to an appropriate level. I seriously fear that we could never get ahead of an outbreak in this manner. Furthermore, there would be no saving in cost.

You point out that the "government can act with dispatch when it needs to protect health," but there seems to be no dispatch in government actions in relation to a wide range of drugs for the treatment of the largest "epidemic" cause of death in the U.S.—cardiovascular disease, including high blood pressure. How do you explain this?

I would caution you about comparing approval and use of a vaccine against swine flu; and FDA approval of drugs, for example against high blood pressure. These are three points here:

First, there are differences between biologicals and other forms of pharmaceuticals, and the requirements for information necessary to certify safety and effectiveness vary.

Second, this is not a new vaccine entirely. Other vaccines have been developed and used against other forms

of influenza for the past 30 years. The only major difference between this one and the others is in the antigenic qualities of the virus itself. It is not as if we were developing a totally new agent here. The information we have regarding toxicity and effectiveness of other influenza vaccines developed and used in recent years is generally applicable to this vaccine against the swine-type virus.

Third, I agree with you that there is also an epidemic of cardiovascular disease to which high blood pressure is contributor. There are also drugs now available in this country which are effective in the control of hypertension, but there is no drug on the market for the practical treatment of influenza, and no specific preparation generally available—yet—for the prevention of the disease caused by the A/New Jersey/76 strain.

Government regulations for new drugs require proof of efficacy and safety even for minor variations in a particular drug class. The government does not approve a drug on the basis of an immunologic or bacteriologic theory or principle, as you indicated for the flu vaccine. Why would you not favor more vigorous action than we have had for almost 10 years in the clearance of new cardiovascular agents?

The fundamental differences between the current vaccine situation and the cardiovascular situation are these:

The swine flu threat is considered to be imminent, and there is no other way to prevent the potential morbidity and mortality except by the proposed measures. With respect to cardiovascular diseases, there are drug treatments already available covering each drug class and each disease factor requiring treatment. The basis of approval for each type of therapeutic agent must rest on sound scientific principles and substantial evidence of safety and effectiveness based upon adequate and well-controlled studies as required by the Food, Drug and Cosmetic Act.

More demonstration of a pharmacologic effect of a cardiovascular agent is insufficient to assure that the particu-

lar agent will be safe and effective in humans, although some predictions in this regard can be made in the case of minor molecular modifications of already existing drug entities. Even in these cases, however, adequate pre-clinical and clinical studies are needed to establish that the predictions are correct.

You have said prevention is the only way to curb high morbidity and mortality from influenza. Do we not also have other means such as improved nutritional status and, of outstanding significance, the availability of antibiotics that are effective against secondary bacterial infections which were a major source of mortality in the 1918-19 epidemic?

Although prevention is the only way to curb high morbidity and mortality from influenza, nutritional status and antibiotic therapy are very important. Antibiotics will most certainly be employed. However, certain strains of flu can cause complications quite rapidly. In such cases, especially in patients with cardiovascular and respiratory disease, antibiotic therapy may be too late or insufficient to prevent morbidity and mortality. The best and most established medical practice is to prevent flu in the first place and use antibiotics as needed.

Theoretically, nutritional status could have some overall effect on influenza disease. However, this would seem to be most important in populations where a high percentage of people were in poor nutritional states, such as populations of developing countries. Nutritional status would not be expected to have a major impact in the United States.

You indicated that there are no drugs on the market for the treatment of influenza but there are for cardiovascular disease. This raises two considerations:

1. Pauling has raised the theoretical point that massive doses of ascorbic acid may be of importance in respect to an epidemic of swine flu because of the effect of ascorbic acid, metal ions and oxygen on nucleic acids and pro-

teins which he maintains "leads to inactivation of viruses and contributes to the control of viral diseases by Vitamin C."

2. Other physicians point to the availability of amantadine. Thus, a nutritional supplement may hypothetically afford some measure of protection over a wider range of viral organisms, in contradistinction to the high specificity of a vaccine. In the other instance, there exists the claim for antiviral effectiveness of a drug for treating an existing viral infection. Furthermore, unpredictability as to whether we will have an epidemic at all or what type it will be is widely acknowledged. Wouldn't it be as logical in support the expertise of such scientists as Pauling as to support the expertise of those who advocate the vaccine? There is debate in both areas. Should the government take a partisan position? If such a partisan position cannot be supported by hard data but by expertise, judgment and theoretical considerations, should not similar criteria be applicable in both instances?

In any position the government takes there is usually going to be a difference of opinion. But the data upon which expert opinion is based must be the best possible. The value of vaccines has already been repeatedly demonstrated. The value of massive doses of vitamins still remains to be established. The OTC Cough and Cold Panel and the OTC Vitamin and Mineral Panel did not find high doses of ascorbic acid to be effective in respiratory disease of viral origin.

Amantadine is one agent that represents a new approach to treatment of viral illnesses. There is some evidence that amantadine can help in symptomatic improvement of infections due to influenza A strains but the mechanism of action is as yet undetermined. Expert medical opinion still does not consider amantadine to be a replacement for vaccine. For patients who cannot take the vaccine, amantadine may be an alternative second choice treatment. Thus, the path that the government has chosen to recommend is based on the best available medical evidence.

Continued Next Issue



On March 24, President Ford, flanked by Dr. Jonas Salk (left), Dr. Cooper, and Dr. Albert Sabin (right), announced and approving an entirely new drug.

Scottish & Newcastle B
Sellope GO Ltd.
Selon Healthcare Group
Shallor Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerville Stores
Sony United Kingdom
St Ival Ltd
Stratford-Upon-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd


"packaging
other exhibi
opportunity
to meet. M
not availab
chance to
discussing
new ideas
Kevin Hyde,
Wells Great

The Boots Com
The Cheese Co
The Invergard
The Koryga
The New Cor
The Rythe Co
The Wellcom
Thomsons P
Thomsons P
Tommy UK Li
Tovall Heal
Trafalgar P
Tranfield o
Treats Gro
Trabon Ba
Tullip Inte
Vilamale
W A Tunn
W Jordan
Walla Gr
Westall A
Whitlow
Wickes
Woolw

ing
Manager
Manager
Manager

WHEN ANXIETY INTERFERES

The cardiac patient and anxiety



"The [cardiac] patient is anxious about minor symptoms, about the implications of his diagnosis, and about real or imagined limitations of function."

The worst is over. The cardiac patient is out of the acute stage, out of the hospital, and well on his way to recovery. How quickly he comes back to near normal functioning may depend on his psychological as well as his physical rehabilitation.

Clinical anxiety, for example, may be one reason for prolonged recuperation following cardiac healing. Yet anxiety can sometimes be beneficial in facilitating patient compliance.


The patient who is realistically concerned about resuming his preoperative functioning may

be highly motivated to adhere to his rehabilitation regimen. However, the cardiac patient with excessive or unresolved anxiety may be so fearful of future heart failure that he refrains from your prescribed regimen.

Excessive anxiety can interfere with patient management

When excessive anxiety diminishes your patient's ability to participate fully in his rehabilitation program, your counseling and reassurance

are often sufficient. But when his anxiety is so great that it actually interferes with his ability to listen and respond, you may wish to consider the addition of an adjunctive antianxiety agent to help reduce his excessive anxiety to more manageable levels.



Librium® (chlordiazepoxide HCl) an effective adjunct to your reassurance and counseling

Safety: Librium has a highly favorable benefits-to-risk ratio and a wide margin of safety. Because of its low incidence of side effects, it is regarded as one of the safest antianxiety agents available. And Librium does not adversely affect the cardiovascular system. See complete product information for warnings, precautions and adverse reactions.

Performance: Hundreds of clinical trials, thousands of published papers, and millions of patients constitute the record of performance for Librium.

Concomitant use: Of special significance in treating the cardiac patient already taking multiple agents is the fact that Librium is used concomitantly with most primary medications, such as cardiac glycosides, diuretics and antihypertensives.

*Zohman BL: *Geriatrics* 28:110-119, Feb 1973

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of anxiety and tension occurring alone or accompanying various disease states.

Contraindications: Patients with known hypersensitivity to the drug.


Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.

Precautions: In the elderly and debilitated, and in children over six, limit to smallest effective dosage (initially 10 mg or less per day) to preclude ataxia or oversedation, increasing gradually as needed and tolerated. Not recommended in children under six. Though generally not recommended, if combination therapy with other psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of potentiating drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Paradoxical reactions (e.g., excitement, stimulation and acute rage) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely in patients receiving the drug and oral anticoagulants; causal relationship has not been established clinically.

Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated. These are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances syncope has been reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and liver function tests advisable during protracted therapy.

Supplied: Librium® Capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCl. Libritab® Tablets containing 5 mg, 10 mg or 25 mg chlordiazepoxide.

ROCHE Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Adjunctive
LIBRIUM® 
chlordiazepoxide HCl/Roche
5 mg, 10 mg, 25 mg capsules

THE ANXIETY-SPECIFIC

Mark Taylor, Project Director
Julian Gorst, Project Manager
John McKee, Project Manager
Vicki Morison, Administration Manager
Isabel Hutchings, Conference Manager
Gladys Benton-Hughes, Conference Manager

Richmond
Surrey TW9 2LS
Tel: 081 332 2422
Fax: 081 332 0939

Scottish & Newcastle
Sellopage GB Ltd
Selen Healthcare Group
Shenley Pen Ltd
Smith & Hephew
Smithline Buecham
Somerfield Stores
Sony Ltd
St Ivel Ltd
Stretford-Upon-Avon
Tele & Lyle Sugars
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhibi
opportunity
to meet. M
not availab
chance to
discussing
new ideas
Kevin Hyde, P
Wells Great E

The Boots Com
The Cheese Co
The Invergord
The Kerrygold
The Now Co
The Ryvita Co
The Welcom
Thorntons P
Thorntons p
Tomy UK Li
Tovall Heal
Trafford Pa
Tranfield o
Treats Gro
Trebort Ba
Tullip Inte
Wilmshel
W A Turn
W Jorda
Wells Gr
Westler
White A
Whitlow
Wicks
Woolwo

Hip Joint Healing May Avoid Surgery

Continued from page 3

ics correlated with the patients improved clinical status.

All of the youngsters, the investigator stressed, had received intensive physical therapy as inpatients in a rehabilitation unit, and all were instructed to maintain a vigorous home exercise program after discharge. All were on a regimen of salicylates and indomethacin, in addition to other anti-arthritis drugs.

Illustrated Case

In a typical history, Dr. Bernstein cited the case of a 12-year-old girl with systemic JRA of nine years' duration, who had severe hip joint pain and needed two canes to walk short distances. Radiographs (see page 1) showed narrowing of the hip joint

spaces and subchondral cysts of both acetabulae and femoral heads.

"Three years later she had no pain, was ambulating without assistance and was able to ride a bicycle," he noted. "Radiography demonstrated widening of joint spaces and sharp cortical margins of the acetabulae and femoral heads.

"In view of the children's improvement," he continued, "it seems unlikely that the increase in joint space was due to joint effusion. Rather, some new articular surface appears to have been provided for joints which previously were almost denuded of cartilage."

Dr. Bernstein observed that a variety of recent studies have challenged the concept that damage to cartilage is irreversible. He cited the widening of

the hip joint that has occurred in some adults following successful femoral osteotomy for osteoarthritis of the hip. Further, he said, experimental studies have shown that the major components of joint cartilage can be renewed even in mature animals; and surgically created defects through cartilage into the subchondral bone may be followed by resurfacing of the joint with tissue having the histologic characteristics of cartilage.

Child's Potential Greater

"It appears possible that, because of a child's greater potential for growth and for remodeling of bone," he declared, "the likelihood of joint restoration is greater than in the adult."

The implications for therapy, his paper suggested, is that an aggressive

rehabilitation program, stressing physical activity, combined with an appropriate medical regimen, offers the most promising chance of joint recovery. Dr. Bernstein commented that in the studies of animals with surgical defects, "new cartilage developed while the animals were permitted free movement; and the cartilage developed at a more rapid pace in the weight-bearing than in the nonweight-bearing areas of the joint. It is possible that a similar situation may have occurred in our patients."

In an interview, Dr. Bernstein's collaborator, Dr. Helen Komreich, Associate Professor of Pediatrics, said the findings suggest that caution should be exercised before radical bone surgery is recommended in patients with JRA. The fact that joint function may be restored in some patients, suggests, she declared, that "we can't always predict the damage is irreversible." Coauthors included Dr. Deborah Forrester.

tumor load that are killed remains constant whether 10^{12} cells are killed with the first dose of drugs, or whether only 10^6 cells are killed. The same dose of drug is needed.

Because of the kinetics of cell division, as zero leukemic cell population is approached, none of the usual rules seem to hold, Dr. Frei said. Some other defense mechanism must then keep the reduced number of leukemic cells from producing any signs or symptoms of the disease in the child.

He suggested that the immune system probably takes hold and keeps the remaining cells in check, keeping the child in continuous remission and free from any clinical signs of leukemia.

The evidence that an abnormally functioning immune system is somehow involved in leukemia is that if the T lymphocytes of the patient (one of the two major classes of immune lymphocytes) fail to kill leukemic lymphocytes, the prognosis for the patient is poor.

This depressed T-cell activity is the single most important indicator of a poor prognosis in the disease, he said.

Fewer Infections

Other poor signs, Dr. Frei said, are identification of the leukemic cell itself as a T-cell, the presence of a mediastinal mass, and a very high white cell count at diagnosis.

Intermittent courses of drug treatment lead to fewer infections than continuous dosing, and they give the blood-forming bone marrow and lymphoid tissues a chance to rest and produce a new population of normal cells, Dr. Frei said.

Dr. Frei cautioned that preliminary studies seem to show that the rate of appearance of second tumors later in life is linked to drugs that disrupt the DNA of the leukemic cells most directly, but not to the antimetabolite drugs, such as folic acid antagonists, that interfere with the protein synthesizing mechanisms of the cell.

Acute Lymphocytic Leukemia Termed a 'Curable Disease'

Medical Tribune Report

WORCESTER, MASS.—Calling acute lymphocytic leukemia in children a "curable disease," Dr. Emil Frei, Director of the Sidney Farber Cancer Institute, Brookline, Mass., told a medical symposium here that if the child receives definitive treatment at a major center specializing in childhood leukemia and remains in complete remission with no relapse for five years, there is only roughly one chance in 10 that a relapse will occur in years five to 10. After 10 years disease free, the probability of relapse is almost nil, Dr. Frei added. Treatment continued longer than two years in these cases offers no advantage in avoiding relapse.

89% Disease Free

Speaking at St. Vincent's Hospital to a symposium on leukemia sponsored by the Leukemia Society of America, Inc., Central Massachusetts Chapter (Worcester), and the hospital, Dr. Frei, Professor of Medicine at Harvard Medical School, reported on 39 children treated at the Sidney Farber Cancer Institute who were taken off their drugs after two or three years of treatment. Thirty-five (89%) of the children are today completely free of disease.

Of four children in the original series (85 children), one died during the initial attempt to induce remission and three others died with a later revised diagnosis of undifferentiated leukemia. Dr. Frei stressed that these last three children had a different disease than the surviving children who had classic acute lymphocytic leukemia (ALL). He said that a review of a similar series from another major cancer center treating large numbers of children with acute leukemia corroborated the results at Sidney Farber. Of roughly 106 children in complete remission, only 10% had a relapse after they were put into remission.

Treatment of acute leukemia in children was "a major success story in cancer chemotherapy," Dr. Frei said. In children with classic ALL, he said, nine out of 10 are alive and disease-free at 36 months. Extrapolating from

earlier series, the survival figure will be 80% at five years and will not be significantly lower at 10 years.

Dr. Frei urged the audience to encourage parents bringing children for treatment to think of the disease as a curable one, although he cautioned that he himself is careful never to tell a parent that his child can be cured, only that the disease is curable.

If the parents are not intimately involved in the treatment plan from the beginning, toxic side-effects of the drugs (falling hair, nausea, vomiting) will add unnecessary psychological burdens to the family, Dr. Frei said.

He said that treatment must be thorough, exact, and should be undertaken only at medical centers with the experience and resources to offer the best chance of successful remission.

Dr. Frei's explanation for successful cure in these cases was that acute lymphocytic leukemia in children, as in all diseases, follows the rule that relapse, if it comes at all, will generally come early in the disease.

The proof of this, he said, is that if treatment is administered early, complications from leukemic cells later invading the brain and spinal cord drop from a rate of 50% to 5% or 10%.

"X-ray treatment to the central nervous system should be factored out of treatment, if possible," he said, adding that various encephalopathies, not well understood, have appeared in some children treated with a combination of high-dose methotrexate and x-ray.

Very high doses of methotrexate without x-ray and followed by a "rescue" drug technique (citrovorum factor) are showing good preliminary results, he said.

Noting that a child at diagnosis carries 10^{12} leukemic cells in his body, Dr. Frei said it is not possible to eradicate the "one" remaining leukemic cell that may still exist after a successful course of chemotherapy. "This is not just looking for a needle in a haystack," he said, "it is looking for an atom in a haystack."

It is important to know, Dr. Frei added, that the percent of cells in the

Asbestos Workers Protest Job-Related Deaths



Protesting the reportedly asbestos-related deaths of 11 fellow workers in 18 months, employees of Johns-Manville Corp., Long Beach, Calif., picketed the plant. Workers want clause in contract to cover asbestos-related illness.

Tribune Economic Analysis

Utility Prices: Bellweather of Stock Trends

By ELIOT JANEWAY
Consulting Economist

Any move in stock prices in which the utilities do not participate is suspect. A unique group, they are the only stocks that combine the characteristics of IBM and government bonds. They were growth stocks before the growth cult came into speculative vogue, and they have always been income stocks. Twenty years ago, every aggressive, professionally-managed portfolio started out with 25% of its assets invested in a cross section of utilities.

The tricky market history of 1976 has been delineated by the utility stocks. During the worst of the bear market, they seemed the least likely candidates for market leadership. Late last year, however, the utilities forged into the forefront as market performers.

The utility stocks ran out of steam last spring. The market realized that the recovery was not building a firm foundation of economic growth free from inflation. Again, the utilities were the bellwether of market performance. Once they stopped going up, the rest of the market started going down.

The realization that utility stocks had become overpriced relative to the cost of inflation prompted many utility stockholders to test the ability of the market to absorb selling. They quickly found that ability lacking, and buying of utilities stopped.

But the investment environment is gradually changing again, this time for the better. It reflects a practical recognition in the money markets that the

In cerebral and peripheral ischemia associated with arterial spasm

Cebral Methaverine HCl 100 mg capsules

In cerebral ischemia: direct vasodilation of cerebral vessels; virtually no CNS effect; rare incidence of side effects permits long-term use

In peripheral vascular disorders: relaxes smooth muscles of larger blood vessels by direct effect unrelated to muscle innervation

For additional product information and professional samples, write on your letterhead to:

K Professional Services Department
KENWOOD LABORATORIES, INC.
New Rochelle, New York 10801

bond market drop was overdone.

Investors who were alarmed by their inability to unload utility stocks last spring are suddenly eyeing them as attractive buys.

Ask Janeway

My son has an ocean front lot in Florida, and has proposed that I invest \$40,000 in a house to be built on it. Do you consider this a wise investment and/or a tax shelter?

Cincinnati Physician

Your son's ocean front lot will be worth more if held with a view to taking money out of it in the future, than if you put money into it now. New homes are still more advantageous to buy than to build. No resort or second home is a tax shelter.

Send your questions on finances, investments, taxes to Janeway, MEDICAL TRIBUNE, 880 Third Avenue, New York, N.Y. 10022.

Simple Lab Tests Aid Diagnosis of Secondary High BP

Medical Tribune Report

DALLAS—A complete medical history, physical examination and simple laboratory testing can provide the physician with a 90% accurate detection of secondary hypertension, Dr. Norman Kaplan, of the American Heart Association, told a meeting here of the Society of Nuclear Medicine.

If the initial examination and tests suggest secondary hypertension, additional testing may be required, said Dr. Kaplan. If, for example, the patient is suspected of having:

- Chronic renal disease, additional tests may include BUN, creatinine and intravenous pyelogram (IVP). If positive, renal assay or renal biopsy.
 - Renovascular disease, tests include IVP and plasma renin. If positive, renal vein renin and aortogram.
 - Coarctation, blood pressure in legs may be taken, followed by aortogram.
 - Primary aldosteronism, testing may include plasma potassium, urinary potassium, plasma renin, plasma or urinary aldosterone.
 - Cushing's syndrome, testing includes plasma 17-OHCS after 1 mg dexamethasone, and urinary 17-OHCS after 0.5 and 2.0 mg dexamethasone every six hours for two days each.
 - Pheochromocytoma, tests may include a spot urine for metanephrine, urinary norepinephrine and epinephrine.
- "No patient will need all of these procedures and relatively few will require any of them," Dr. Kaplan said. However, since idiopathic hypertension is incurable, attempts should be made to identify reversible forms.

ILXB12

hematinics of choice

By teaspoon or tablet

- Readily assimilated
- Well tolerated
- Economical

Usual Dosage: ELIXIR—1 to 8 teaspoonsful daily or as directed by physician.
TABLETS—1 tablet 3 times a day or as directed by physician.
Supplied: 12 ounce bottles of Elixir; bottles of 100 Tablets

K Kenwood Laboratories, Inc., New Rochelle, New York 10801
developers and suppliers of Cebral and Kengesin

for nutritional and iron deficiency anemias

ILXB12
Elixir—each ounce represents: Iron and Ammonium Chloride, 18 gr.; Liver Fraction 1, 3 gr.; Thiamine Hydrochloride, 10 mg.; Riboflavin, 4 mg.; Nicotinamide, 20 mg.; Cyanocobalamin (Vit. B12), 20 mcg.; Alcohol 8% by volume.
Tablets—each tablet contains: Ferrous Gluconate, 5 gr.; Vitamin C, 60 mg.; Cyanocobalamin (Vit. B12), 10 mcg.; Liver Fraction 2, 2 gr.; Thiamine Hydrochloride, 2 mg.; Riboflavin, 2 mg.; Nicotinamide, 20 mg.


Mark Wayne
Julien Gort Project Director
John McKee Project Manager
Vicki Morrison Administration Manager
Isabel Hutchings Conference Manager
Benton-Hughes Conference Assistant

mond
ray TW9 2LS


at: 081 332 2422
ax: 081 332 0939

Valium® differs from other benzodiazepines (diazepam)


Valium (diazepam) is the one benzodiazepine with three clinically useful pharmacologic properties In the research laboratory, Valium demonstrated that it possessed potent psychotherapeutic, muscle relaxant and anticonvulsant properties. But the crucial question remained: would these three properties prove to be clinically useful? Extensive clinical testing gave the answer. Yes. Of all the available benzodiazepines, Valium — and only Valium — has three valuable pharmacologic properties that have all proven to have definite clinical utility. Clearly, this makes Valium one of the most useful agents in a physician's armamentarium. And, quite likely, one of the most versatile. Today, Valium is indicated in an impressively broad



range of disorders. As a psychotherapeutic agent, for instance, it's useful for the relief of undue psychic tension and anxiety whether seen alone or associated with organic and functional disorders. It's also useful in psychoneurotic conditions evidenced by anxiety with or without secondary depressive symptoms. Because of its skeletal muscle relaxant effect, Valium is a valuable adjunct in relieving skeletal muscle spasm caused by strains, sprains or inflamed skeletal muscles. And its potent anticonvulsant action makes it a preferred drug (given adjunctively I.V.) in status epilepticus. Drowsiness, ataxia and fatigue are possible side effects, but these and more serious adverse reactions are rarely a problem. Of course, as with all CNS-acting agents, patients should be cautioned about driving, operating dangerous machines or the simultaneous ingestion of alcohol while taking Valium (diazepam).




Injectable Valium has distinct anticonvulsant properties. Sample of EEG's in a patient with status epilepticus — before and 15 seconds after Valium 8 mg I.V. Lombroso CT: *Neurology* 16:629-634, July 1966.



Preliminary studies in both animals and humans have suggested that Valium may also work at the spinal level by enhancing presynaptic inhibition, a mechanism believed to diminish spasm in skeletal muscle.

Only Valium (diazepam) has a pharmacokinetic profile that includes diazepam, active itself, plus other active metabolites



The unique metabolic pathways of Valium (diazepam)

2-mg, 5-mg, 10-mg scored tablets
2-ml Tel-E-Ject® disposable syringes } 5 mg/ml
2-ml ampuls }
10-ml vials }



Because the various benzodiazepines all have different physical-chemical properties, each, naturally, has a different pharmacokinetic "profile." The "profile" of Valium stands out for a number of reasons. First and foremost is the fact that the major metabolites of Valium, which include desmethyldiazepam, 3-hydroxydiazepam and oxazepam, are all pharmacologically active. And, of course, the parent substance — diazepam itself — is also highly active. Then, too, Valium has demonstrated a highly reliable and consistent pattern of absorption, distribution, metabolism and excretion. Such pharmacokinetic predictability is just one more indication of its overall reliability of performance.

Valium® (diazepam) ^{IV}

One of a kind.

Please turn page for a summary of product information.

2-mg, 5-mg, 10-mg scored tablets
2-ml Tel-E-Ject® disposable syringes
2-ml ampuls
10-ml vials

} 5mg/ml

- INJECTABLE:** Laryngospasm and increased cough reflex are possible during peroral endoscopic procedures; use topical anesthetic and have necessary countermeasures available; hypotension or muscular weakness possible, particularly when used with narcotics, barbiturates or alcohol. Use lower doses (2 to 5 mg) for elderly and debilitated; safety

A cartoon illustration by Charles Chilton. On the left, a man in a white lab coat sits in a wooden chair, looking towards the center. In the middle, a man with wild hair and a white lab coat points his right index finger towards the right. A speech bubble above him says "OVER THERE". On the right, a man with glasses and a white lab coat sits behind a desk, looking towards the man in the middle. The floor is covered with a pattern of small, dark, circular objects. The signature "CHILTON" is in the bottom right corner.

Physicians of both sexes and all nationalities are invited to participate in international cycling race, like above, to be at Grammont, Belgium, Sept. 10-12, national cycling race, like above, to be at Grammont, Belgium, Sept. 10-12, sponsored by La Tribune Médicale, the French edition of MEDICAL TRIBUNE. Over 300 are registered already in race which will go 49 to 70 kilometers depending on entrant's age. Register before August 15, 1976, by writing to Association Cyclistes Des Corps Sants, 10' Place Payron, Marines, France.

Both men urge posting of warnings on steam bath doors.

While many have characterized "Rucky" as a genius, it's an appella-

Patient had tubular breath sounds